INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1501, 0, 'Obinutuzumab', 'Hepatitis B', 'The use of anti-CD20 antibodies has caused reactivation of hepatitis B virus, in some cases with fatal outcomes.  It is recommended to screen all patients for hepatitis B virus infection before initiating treatment.  Monitor patients during, and after several months for hepatitis B virus infection according to clinical practice.  Discontinue these agents immediately and institute appropriate treatment if patients develop reactivation of hepatitis B virus while on therapy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1502, 0, 'Obinutuzumab', 'Leukoencephalopathy, Progressive Multifocal', 'Serious infections, including reactivation of viral infections, have been reported with the use of anti-CD20 antibodies.  JC virus infections resulting in progressive multifocal leukoencephalopathy (PML) have been reported in patients treated with these agents.  A diagnosis of PML should be considered in any patient presenting with new-onset neurological manifestations, and a consultation with a neurologist is recommended.  Care should be exercised when giving these drugs to patients with a history of recurring or chronic infections as they are at an increased risk of infections.  Do not start therapy in patients with an active infection.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1503, 0, 'Obinutuzumab', 'Tumor Lysis Syndrome', 'Tumor lysis syndrome (TLS) has occurred in patients receiving certain monoclonal antibodies.  Patients with high tumor burden and those with high circulating lymphocyte counts of greater than 25 X 10^9/L have a higher risk of developing TLS.  Consider tumor lysis prophylaxis prior to the infusion with anti-hyperuricemics and hydration beginning 12 to 24 hours prior to infusion.  It is recommended to correct electrolytes abnormalities, and monitor renal function in patients who develop TLS.  Monitor for signs and symptoms of TLS and temporary interruption or discontinuation of therapy might be required.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1504, 0, 'Obinutuzumab', 'Pulmonary Heart Disease', 'Patients with a prior history of cardiac or pulmonary disease should be closely monitored during and after the infusion of anti-CD20 antibodies as they can increase the risk of presenting a severe and life-threatening infusion reaction.  Therapy with these agents should be permanently discontinued in patients presenting any Grade 4 infusion reactions and for those presenting Grade 3, interrupt therapy and institute treatment according to clinical guidelines.  The rate of infusion should be reduced for those patients presenting Grade 1, or 2 reactions.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1505, 0, 'Obinutuzumab', 'Pancytopenia', 'Severe neutropenia, thrombocytopenia, and anemia have been documented with the use of anti-CD20 antibodies.  Monitor complete blood counts during and after therapy according to clinical guidelines.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1506, 0, 'Atomoxetine', 'Glaucoma, Angle-Closure', 'The use of atomoxetine is contraindicated in patients with narrow angle glaucoma.  In clinical trials, atomoxetine use was associated with an increased risk of mydriasis.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1507, 0, 'Atomoxetine', 'Heart Diseases', 'The use of CNS stimulants is contraindicated in patients with significant cardiovascular impairment such as uncompensated heart failure, severe coronary disease, severe hypertension (including that associated with hyperthyroidism or pheochromocytoma), cardiac structural abnormalities, serious arrhythmias, etc.  Sudden death has been reported in adults and children taking CNS stimulant treatment.  Additionally, stroke, myocardial infarction, chest pain, syncope, arrhythmias and other symptoms have been reported in adults under treatment.  A careful assessment of the cardiovascular status should be done in patients being considered for treatment.  This includes family history, physical exam and further cardiac evaluation (EKG and echocardiogram).  Patients who develop symptoms should have a detailed cardiac evaluation and if needed, treatment should be suspended.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1508, 0, 'Atomoxetine', 'Glaucoma', 'The use of most CNS stimulants is contraindicated in patients with glaucoma, as these agents exhibit sympathomimetic activity and may induce mydriasis provoking an increase in intraocular pressure.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1509, 0, 'Atomoxetine', 'Hypertension', 'CNS stimulant medications have shown to increase blood pressure, and their use might be contraindicated in patients with severe hypertension.  Caution should be used when administering to patients with preexisting high blood pressure and other cardiovascular conditions.  All patients under treatment should be regularly monitored for changes in blood pressure and heart rate.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1510, 0, 'Atomoxetine', 'Liver Diseases', 'In general, CNS stimulants are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with CNS stimulants should be administered cautiously in patients with moderate to severe liver disease, and the dosage should be adjusted accordingly.  Additionally, postmarketing reports have shown that atomoxetine can cause severe liver injury.  Laboratory testing should be done at the first sign or symptom of liver dysfunction (jaundice, dark urine, upper quadrant tenderness) and treatment should be discontinued in patients with evidence of liver injury.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1511, 0, 'Atomoxetine', 'Mental Disorders', 'The use of CNS stimulants can cause psychotic or maniac symptoms, suicidal ideation, aggression and can exacerbate symptoms of behavior disturbance and thought disorder.  Psychiatric symptoms have been reported in patients with and without history of psychiatric disorders, and all patients should be monitored closely, specially during treatment initiation and at times of dose changes.  Extreme caution should be exercised when CNS stimulants are given to patients with a history of psychosis, depression, mania, or bipolar disorder.  All patients receiving treatment should be screened for bipolar disease prior to initiation.  If any psychiatric symptoms emerge or are exacerbated, treatment suspension should be considered.  CNS stimulants are contraindicated in patients with marked agitation or anxiety.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1512, 0, 'Atomoxetine', 'Bipolar Disorder', 'Central nervous system (CNS) stimulants may induce a mixed/manic episode in patients with bipolar disorder.  Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression).  Close monitoring is recommended when using these agents in patients with bipolar disorders.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1513, 0, 'Atomoxetine', 'Psychotic Disorders', 'Central nervous system (CNS) stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder.  Close monitoring is recommended when using these agents in patients with psychotic disorders.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1514, 0, 'Atomoxetine', 'Kidney Diseases', 'Overall CNS stimulants should be administered with caution in patients with significantly impaired renal function as the reduction in the rate of elimination may alter the therapeutic response.  The dosage should be adjusted accordingly.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1515, 0, 'Atomoxetine', 'Epilepsy', 'Due to general central nervous system stimulation, therapy with CNS stimulant drugs may cause seizures.  These drugs may lower the convulsive threshold in patients with prior history of seizures or EEG abnormalities, and very rarely in patients with no previous history of seizures.  Therapy with CNS stimulants should be used with caution in patients with or predisposed to seizures.  If seizures appear, therapy should be discontinued.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1516, 0, 'Atomoxetine', 'Urinary Retention', 'There have been reports of urinary retention and urinary hesitation in ADHD patients using atomoxetine.  Caution should be used if any urinary symptoms appear, especially in patients with history of urinary disorders.', '1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1517, 0, 'Ocrelizumab', 'Hepatitis B', 'The use of ocrelizumab is contraindicated in patients with an active hepatitis B virus (HBV) infection.  It is recommended to consult a liver disease expert before starting and during treatment with ocrelizumab in patients who are negative for surface antigen [HBsAg] and positive for HB core antibody [HBcAb+] or are carriers of HBV [HBsAg+].', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1518, 0, 'Ocrelizumab', 'Breast Neoplasms', 'Ocrelizumab may increase the risk of malignancies, including breast cancer.  It is recommended to follow standard breast cancer screening guidelines.  Exercise care when using this agent in patients with a history of breast cancer or other type of malignancy.  Monitor closely for the development of any sign or symptom suggestive of a malignancy and treat appropriately.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1519, 0, 'Ocrelizumab', 'Infections', 'Ocrelizumab may increase the risk for upper respiratory tract infections, lower respiratory tract infections, skin infections, and herpes-related infections.  It is recommended to delay the use of ocrelizumab in patients with an active infection until the infection is resolved.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1520, 0, 'Octreotide', 'Kidney Diseases', 'Octreotide is eliminated by the kidney.  Approximately 30% of octreotide is excreted unchanged in the urine.  The serum concentration of octreotide and the half-life is increased in patients with severe renal dysfunction.  Therapy with octreotide should be administered cautiously and dosage modification considered in patients with severe renal impairment as the half-life of octreotide may be increased, necessitating adjustment of the dosage.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1521, 0, 'Octreotide', 'Gallbladder Diseases', 'Octreotide inhibits gallbladder contractility and may alter bile composition.  An average of 29% of patients develop new gallstones during octreotide therapy, and up to 20% of patients develop biliary sludge.  Associated pancreatitis has been reported in rare cases.  Gallbladder hypercontractility, sometimes resulting in biliary colic, has been reported upon withdrawal of octreotide.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1522, 0, 'Octreotide', 'Glucose Intolerance', 'The incidence of hypoglycemia may increase during octreotide therapy due to inhibition of glucagon and growth hormone.  Hyper- and hypoglycemia have been associated with the use of octreotide in nondiabetic patients with acromegaly.  Clinical monitoring of blood glucose is recommended in patients with diabetes or insulinoma.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1523, 0, 'Octreotide', 'Heart Diseases', 'Bradycardia, arrhythmias and conduction abnormalities, including QT prolongation have been reported with the use of octreotide.  Patients taking other drugs that have bradycardic effects may need dose adjustments.  Caution is recommended in patients with cardiac function abnormalities.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1524, 0, 'Octreotide', 'Hepatic Insufficiency', 'The half-life of octreotide may be increased in patients with liver cirrhosis, necessitating adjustment of dosage.  This dose should be up titrated based on clinical response and speed of response as deemed necessary by the physician.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1525, 0, 'Octreotide', 'Hypothyroidism', 'Rarely, hypothyroidism requiring thyroid hormone replacement may occur during chronic therapy.  More commonly, a statistically significant, but usually clinically insignificant, increase in TSH may be observed, possibly caused by slight inhibition of peripheral deiodination of thyroxin.  Therapy with octreotide should be administered cautiously to patients with uncontrolled thyroid disorders.  Clinical monitoring of thyroid function is recommended.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1526, 0, 'Octreotide', 'Vitamin B 12 Deficiency', 'Decreased serum concentrations of vitamin B12 have occurred during chronic administration of octreotide.   Therapy with octreotide should be administered cautiously to patients with uncontrolled vitamin B12 deficiency.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1527, 0, 'Ofatumumab', 'Hepatitis B', 'The use of anti-CD20 antibodies has caused reactivation of hepatitis B virus, in some cases with fatal outcomes.  It is recommended to screen all patients for hepatitis B virus infection before initiating treatment.  Monitor patients during, and after several months for hepatitis B virus infection according to clinical practice.  Discontinue these agents immediately and institute appropriate treatment if patients develop reactivation of hepatitis B virus while on therapy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1528, 0, 'Ofatumumab', 'Leukoencephalopathy, Progressive Multifocal', 'Serious infections, including reactivation of viral infections, have been reported with the use of anti-CD20 antibodies.  JC virus infections resulting in progressive multifocal leukoencephalopathy (PML) have been reported in patients treated with these agents.  A diagnosis of PML should be considered in any patient presenting with new-onset neurological manifestations, and a consultation with a neurologist is recommended.  Care should be exercised when giving these drugs to patients with a history of recurring or chronic infections as they are at an increased risk of infections.  Do not start therapy in patients with an active infection.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1529, 0, 'Ofatumumab', 'Tumor Lysis Syndrome', 'Tumor lysis syndrome (TLS) has occurred in patients receiving certain monoclonal antibodies.  Patients with high tumor burden and those with high circulating lymphocyte counts of greater than 25 X 10^9/L have a higher risk of developing TLS.  Consider tumor lysis prophylaxis prior to the infusion with anti-hyperuricemics and hydration beginning 12 to 24 hours prior to infusion.  It is recommended to correct electrolytes abnormalities, and monitor renal function in patients who develop TLS.  Monitor for signs and symptoms of TLS and temporary interruption or discontinuation of therapy might be required.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1530, 0, 'Ofatumumab', 'Pulmonary Heart Disease', 'Patients with a prior history of cardiac or pulmonary disease should be closely monitored during and after the infusion of anti-CD20 antibodies as they can increase the risk of presenting a severe and life-threatening infusion reaction.  Therapy with these agents should be permanently discontinued in patients presenting any Grade 4 infusion reactions and for those presenting Grade 3, interrupt therapy and institute treatment according to clinical guidelines.  The rate of infusion should be reduced for those patients presenting Grade 1, or 2 reactions.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1531, 0, 'Ofatumumab', 'Pancytopenia', 'Severe neutropenia, thrombocytopenia, and anemia have been documented with the use of anti-CD20 antibodies.  Monitor complete blood counts during and after therapy according to clinical guidelines.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1532, 0, 'Olsalazine', 'Kidney Diseases', 'The use of mesalamine and other compounds which contain or are converted to mesalamine has rarely been associated with renal adverse effects, including minimal change nephropathy, acute and chronic interstitial nephritis, and nephrogenic diabetes insipidus.  Renal lesions such as renal infarct, papillary necrosis, tubular necrosis and interstitial fibrosis have been reported in high-dose animal studies.  Therapy with mesalamine and prodrugs of mesalamine should be administered cautiously in patients with impaired renal function or a history of renal disease.  Renal function should be evaluated prior to initiation of therapy and periodically during therapy.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1533, 0, 'Olopatadine (nasal)', 'Alcoholism', 'Concurrent use of olopatadine nasal spray with alcohol or other central nervous system depressants should be avoided as additional reductions in alertness and additional impairment of the central nervous system performance may occur.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1534, 0, 'Olmesartan', 'Angioedema', 'The use of these agents is contraindicated in patients with a history of angioedema related to previous angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) therapy or in patients with hereditary angioedema.  Patients with a history of angioedema unrelated to these agents may be at increased risk of angioedema while receiving angiotensin II receptor (AR) antagonists.  Patients should be advised to immediately report any signs or symptoms suggestive of angioedema (swelling of face, extremities, eyes, lips, or tongue, or difficulty swallowing or breathing) and to stop taking the medication until otherwise directed by their physician.  Emergency therapy and/or measures to prevent airway obstruction are required for angioedema involving the tongue, glottis, or larynx.  Treatment with angiotensin II receptor (AR) antagonists should be discontinued permanently if angioedema develops in association with therapy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1535, 0, 'Olmesartan', 'Hypotension', 'Angiotensin II receptor (AR) antagonists can cause symptomatic hypotension in patients with an activated renin-angiotensin system, such as volume- and/or sodium-depleted patients.  Therapy with AR antagonists should be administered cautiously in such patients and in those predisposed to hypovolemic or hyponatremic states (e.g., patients on diuretic therapy, especially if high doses were used or if recently instituted; those on dietary salt restriction; renal dialysis patients).  Volume and/or sodium depletion should be corrected prior to initiating therapy with AR antagonists, and the patient should be hemodynamically stable.  Ideally, patients at risk for excessive hypotension should initiate AR antagonist therapy under close medical supervision, preferably with a lower dose, and followed closely for the first 2 weeks of treatment and whenever the dosage of AR antagonist or diuretic is increased.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1536, 0, 'Olmesartan', 'Heart Failure', 'Angiotensin II receptor (AR) antagonists can cause renal impairment in patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system.  In addition, symptomatic hypotension can occur in susceptible individuals, which may compromise renal and myocardial perfusion.  In patients with severe congestive heart failure (CHF), treatment with AR antagonists has been associated with oliguria and/or progressive azotemia and, rarely, renal failure, myocardial ischemia, and death.  Therapy with AR antagonists should be initiated cautiously in patients with severe CHF, especially when accompanied by volume and/or sodium depletion.  In patients who experience a decline in renal function, discontinuation of AR antagonist therapy is usually not required provided there is symptomatic improvement of the heart failure and renal deterioration is well-tolerated.  Transient hypotension is also not a contraindication to further treatment with AR antagonists, since therapy can usually be reinstated without difficulty after blood pressure stabilizes.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1537, 0, 'Olmesartan', 'Hyperkalemia', 'Drugs that inhibit the renin-angiotensin, such as angiotensin II receptor antagonist system can cause hyperkalemia.  Concomitant use of these agents with drugs that increase potassium levels may increase the risk of hyperkalemia.  Use caution when using these agents together and monitor serum potassium periodically.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1538, 0, 'Olmesartan', 'Renal Artery Obstruction', 'In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, angiotensin II receptor (AR) antagonists may reduce renal perfusion to a critically low level.  Increases in serum creatinine or blood urea nitrogen have been reported with ACE inhibitors, a class of drugs that also block the renin-angiotensin-aldosterone system.  Although there are no long-term data on the use of AR antagonists in patients with renal artery stenosis, a similar effect should be anticipated.  Renal function should be monitored closely for the first few weeks of therapy.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1539, 0, 'Olmesartan', 'Kidney Diseases', 'Changes in renal function including acute renal failure can be caused by drugs that inhibit the renin-angiotensin system and by diuretics.  Patients whose renal function may depend in part on the activity of the renin-angiotensin system (e.g., patients with renal artery stenosis, chronic kidney disease, severe congestive heart failure, or volume depletion) may be at particular risk of developing acute renal failure with these agents.  Monitor renal function periodically in these patients.  Consider withholding or discontinuing therapy in patients who develop a clinically significant decrease in renal function with these agents.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1540, 0, 'Olmesartan', 'Liver Diseases', 'Olmesartan is eliminated unchanged in the urine and bile.  After repeated dosing in patients with severe renal impairment (CrCl < 20 mL/min), the systemic exposure (AUC) was approximately tripled compared to subjects with normal renal function.  In patients with moderate hepatic impairment, the AUC increased about 60% relative to that in matched controls.  The manufacturer states that no initial dosage adjustment is necessary in patients with moderate to marked renal or hepatic impairment.  However, patients should be monitored for undue adverse effects of the drug.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1541, 0, 'Ofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1542, 0, 'Ofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1543, 0, 'Ofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1544, 0, 'Ofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1545, 0, 'Ofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1546, 0, 'Ofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1547, 0, 'Ofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1548, 0, 'Ofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1549, 0, 'Ofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1550, 0, 'Ofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1551, 0, 'Atovaquone', 'Gastrointestinal Diseases', 'Oral bioavailability of atovaquone is limited under fasting conditions, but is increased approximately two-fold when administered with food.  Patients with gastrointestinal disorders or eating difficulties may be more likely to have impaired absorption and, consequently, subtherapeutic levels of the drug.   Alternative parenteral treatment should be considered for patients unable to achieve adequate plasma concentrations of atovaquone with oral administration.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1552, 0, 'Atovaquone', 'Liver Diseases', 'Atovaquone may cause elevated liver function tests.  In clinical trials, elevated serum alkaline phosphatase concentrations (> 2.5 times the upper limit of normal, or ULN) were reported in approximately 8% of patients, and elevations in serum ALT and AST (> 5 times ULN) were reported in 6% and 4% of patients, respectively.  Increases in serum bilirubin has occurred rarely.  Atovaquone also may undergo limited metabolism by the liver.  Therapy with atovaquone should be administered cautiously in patients with severe hepatic impairment.  Liver function tests should be performed periodically, and therapy withdrawn if significant elevations develop.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1553, 0, 'Omalizumab', 'Neoplasms', 'In clinical trials malignancies have been observed in patients receiving omalizumab.  Periodic examination is recommended for all patients, particularly those with risk factors for cancer.  Caution should be exercised when considering omalizumab for the treatment of patients with a history of malignancies, those who have a known malignancy, or when continuing treatment in patients who develop malignancy while receiving this agent.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1554, 0, 'Olodaterol', 'Asthma', 'Long acting beta- 2 adrenergic antagonists (LABA) increase the risk of asthma related death.  Olodaterol inhalation spray is not indicated to treat asthma.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1555, 0, 'Olodaterol', 'Hepatic Insufficiency', 'Some long acting beta- 2 adrenergic agonists (LABA) such as arformoterol and olodaterol should be used with caution in patients with hepatic impairment due to increased systemic exposure.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1556, 0, 'Olodaterol', 'Cardiovascular Diseases', 'Adrenergic bronchodilators can stimulate cardiovascular beta- 1 and beta- 2 receptors, resulting in adverse effects such as tachycardia, palpitation, peripheral vasodilation, blood pressure changes, and ECG changes (e.g., flattening of the T wave; prolongation of the QT interval; ST segment depression).  Direct stimulation of cardiac tissues is mediated by beta- 1 receptors and thus less likely to occur with beta-2-selective agents such as albuterol.  However, beta-2-selectivity is not absolute and can be lost with larger doses.  High dosages of these agents have been associated with precipitation or aggravation of angina, myocardial ischemia, and cardiac arrhythmias.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, and/or underlying cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, or hypertension.  The recommended dosages should not be exceeded.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1557, 0, 'Olodaterol', 'Diabetes Mellitus', 'Adrenergic bronchodilators may cause increases in blood glucose concentrations.  These effects are usually transient and slight, but may be significant with dosages higher than those normally recommended.  Large doses of IV albuterol (not commercially available in the U.S.) and terbutaline sulfate have been reported to cause exacerbation of preexisting diabetes mellitus and ketoacidosis.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with diabetes mellitus.  Closer monitoring of blood glucose concentrations may be appropriate.  Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1558, 0, 'Olodaterol', 'Hypokalemia', 'Adrenergic bronchodilators may cause decreases in serum potassium concentrations, primarily when given by nebulization or intravenous administration.  Although this effect is usually transient and does not require supplementation, clinically significant hypokalemia may occur in some patients, with the potential to induce cardiovascular adverse effects.  The relevance of these observations to oral or oral aerosol/powder for inhalation therapy is unknown.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with or predisposed to hypokalemia.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1559, 0, 'Olodaterol', 'Seizures', 'Adrenergic bronchodilators may cause CNS stimulation.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with seizure disorders.  Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1560, 0, 'Olaratumab', 'Hepatic Insufficiency', 'Olaratumab population pharmacokinetic analysis in patients with mild to moderate hepatic impairment indicated that hepatic impairment had no clinically important effect on the pharmacokinetics of olaratumab.  The pharmacokinetics of olaratumab in patients with severe hepatic impairment is unknown.  Care and close monitoring should be exercised when using this agent in patients with severe hepatic impairment.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1561, 0, 'Olaratumab', 'Kidney Diseases', 'Olaratumab population pharmacokinetic analysis in patients with mild to moderate renal impairment indicated that renal impairment had no clinically important effect on the pharmacokinetics of olaratumab.  The pharmacokinetics of olaratumab in patients with severe renal impairment is unknown.  Care and close monitoring should be exercised when using this agent in patients with severe renal impairment.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1562, 0, 'Atorvastatin', 'Liver Diseases', 'The use of HMG-CoA reductase inhibitors is contraindicated in patients with active liver disease or unexplained, persistent elevations of serum transaminases.  HMG-CoA reductase inhibitors are extensively metabolized by the liver.  Decreased drug metabolism may lead to accumulation and increased risk of toxicity, including biochemical abnormalities of liver function and, rarely, jaundice, hepatitis, cirrhosis, fatty change in the liver, and fulminant hepatic necrosis.  Therapy with HMG-CoA reductase inhibitors should be administered cautiously in patients with a history of liver disease and/or heavy alcohol use.  A lower initial dosage may be appropriate, and clinical monitoring of liver transaminase levels according to the individual product package labeling is recommended.  Patients who develop elevated  ALT or AST levels during therapy should be monitored until abnormalities resolve.  If an increase above 3 times the upper limit of normal persists, consideration should be given to a reduction in dosage or withdrawal of therapy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1563, 0, 'Atorvastatin', 'Rhabdomyolysis', 'Severe myopathy, including rhabdomyolysis with acute renal failure secondary to myoglobinuria, has been reported rarely with the use of HMG-CoA reductase inhibitors.  The myopathy may be dose-related and is characterized by muscle aches and/or weakness in conjunction with increases in creatine phosphokinase (CPK) values exceeding 10 times the upper limit of normal.  Therapy with HMG-CoA reductase inhibitors should be administered cautiously in patients with preexisting myopathy, in those with predisposing factors for myopathy or with a history of myoneural disorder, since it may delay the recognition or confound the diagnosis of a drug-induced musculoskeletal effect.  Patients should be advised to report promptly any unusual muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.  Periodic CPK determinations may be considered in some patients, although the value of such monitoring is uncertain.  HMG-CoA reductase inhibitor therapy should be withdrawn if markedly elevated CPK levels occur or if drug-related myopathy is diagnosed or suspected.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1564, 0, 'Atorvastatin', 'Cognitive Dysfunction', 'Cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, confusion) have been observed in patients receiving statins.  The reports are usually not serious, and reversible upon statin discontinuation.  Caution is recommended when using these agents in patients with cognitive impairment.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1565, 0, 'Atorvastatin', 'Diabetes Mellitus', 'Increases in HbA1c and fasting serum glucose levels have been reported with the use of certain HMG-CoA reductase inhibitors.  Caution should be exercised when using these agents in diabetic patients and close monitoring is recommended.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1566, 0, 'Atorvastatin', 'Kidney Diseases', 'Some HMG-CoA reductase inhibitors such as fluvastatin, have not been studied in patients with severe renal impairment or end-stage renal disease.  Some others such as pitavastatin and simvastatin, require a dose reduction when used in this group of patients.  Caution and close monitoring is advised when using these drugs in patients with renal impairment.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1567, 0, 'Omeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1568, 0, 'Omeprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1569, 0, 'Omeprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1570, 0, 'Onasemnogene abeparvovec', 'Liver Diseases', 'The use of onasemnogene abeparvovec-xioi can increase liver enzyme levels and cause acute serious liver injury.  Close monitoring is recommended in patients with pre-existing liver impairment as they may be at higher risk.  It is recommended to assess liver function of all patients by clinical examination and laboratory testing (e.g., hepatic aminotransferases [aspartate aminotransferase (AST) and alanine aminotransferase (ALT)], total bilirubin, and prothrombin time) prior to infusion.  Continue to monitor liver function for at least 3 months after infusion; weekly for the first month, and then every other week for the second and third months, until results are unremarkable.  Administer systemic corticosteroid to all patients before and after onasemnogene abeparvovec-xioi infusion.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1571, 0, 'Onasemnogene abeparvovec', 'Cardiotoxicity', 'In clinical trials, transient increases in cardiac troponin-I levels (up to 0.176 g/L) were observed following onasemnogene abeparvovec-xioi infusion.  The clinical importance of these findings is not known; however, cardiac toxicity was observed in animal studies.  Care should be exercised in patients at risk.  It is recommended to monitor troponin-I before infusion and weekly for the first month, and then monthly for the second and third months until troponin-I level returns to baseline as appropriate.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1572, 0, 'Onasemnogene abeparvovec', 'Thrombocytopenia', 'Transient decreases in platelet counts, some of which met the criteria for thrombocytopenia, were observed at different time points after onasemnogene abeparvovec-xioi infusion.  Care should be exercised in patients at risk.  It is recommended to monitor platelet counts before the infusion and weekly for the first month; every other week for the second and third months until platelet counts return to baseline as appropriate.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1573, 0, 'Olanzapine', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1574, 0, 'Olanzapine', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1575, 0, 'Olanzapine', 'Respiratory Insufficiency', 'The use of neuroleptic agents is contraindicated in comatose patients and patients with severe central nervous system depression.  Neuroleptic agents may potentiate the CNS and respiratory depression in these patients.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1576, 0, 'Olanzapine', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of neuroleptic agents may precipitate or aggravate a potentially fatal symptom complex known as neuroleptic malignant syndrome (NMS).  NMS is observed most frequently when high-potency agents like haloperidol are administered intramuscularly, but may occur with any neuroleptic agent given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure.  Neuroleptic agents should not be given to patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of neuroleptic agents should be carefully considered, since NMS may recur.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1577, 0, 'Olanzapine', 'Pneumonia, Aspiration', 'Esophageal dysmotility and aspiration have been associated with the use of antipsychotic drugs.  These drugs should be administered cautiously in patients at risk for aspiration pneumonia.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1578, 0, 'Olanzapine', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1579, 0, 'Olanzapine', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1580, 0, 'Olanzapine', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1581, 0, 'Olanzapine', 'Hypotension', 'The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope.  Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1582, 0, 'Olanzapine', 'Dyslipidemias', 'Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  Before or soon after initiation of antipsychotic medications, a fasting lipid profile should be obtained at baseline and monitored periodically during treatment.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1583, 0, 'Olanzapine', 'Weight Gain', 'Weight gain has been observed with atypical antipsychotic use.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  When treating pediatric patients with atypical antipsychotic agents, weight gain should be monitored and assessed against that expected for normal growth.  Monitor weight at baseline and frequently thereafter.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1584, 0, 'Olanzapine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1585, 0, 'Olanzapine', 'Anticholinergic Syndrome', 'Most neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low- potency agents such as chlorpromazine and thioridazine tend to exhibit the greatest degree of anticholinergic effects in the class, while haloperidol as well as the newer, atypical agents like quetiapine, risperidone and ziprasidone have generally been associated with very low frequencies of anticholinergic adverse effects.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1586, 0, 'Olanzapine', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1587, 0, 'Olanzapine', 'Liver Diseases', 'Most neuroleptic agents are extensively metabolized by the liver.  The plasma concentrations of these agents may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with neuroleptic agents should be administered cautiously in patients with significant liver disease.  Lower initial dosages and slower titration may be appropriate.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1588, 0, 'Olanzapine', 'Parkinsonian Disorders', 'The use of neuroleptic agents is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Older neuroleptic agents such as haloperidol are more likely to induce these effects, and their use may be contraindicated in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1589, 0, 'Olanzapine', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1590, 0, 'Olanzapine', 'Phenylketonurias', 'Zyprexa Zydis (brand of olanzapine orally distintegrating tablets) contains 0.34 mg and 0.45 mg of phenylalanine per each 5 mg and 10 mg tablet, respectively.  The phenylalanine content should be considered when this and similar products are used in patients who must restrict their intake of phenylalanine (i.e. phenylketonurics).', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1591, 0, 'Oliceridine', 'Gastrointestinal Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the gastrointestinal tract and decrease peristalsis, which can lead to elevated intraluminal pressure, spasm, and constipation following prolonged use.  In patients with severe or acute inflammatory bowel disease, the decrease in colonic motility may induce toxic megacolon.  Therapy with opioids should be administered cautiously in patients with gastrointestinal obstruction, constipation, inflammatory bowel disease, or recent gastrointestinal tract surgery.  Gastrointestinal effects appear to be the most pronounced with morphine.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1592, 0, 'Oliceridine', 'Alcoholic Intoxication', 'The use of opiate agonists is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of opiate agonists may be additive with those of alcohol.  Severe respiratory depression and death may occur.  Therapy with opiate agonists should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1593, 0, 'Oliceridine', 'Substance-Related Disorders', 'Opiate agonists have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop after prolonged use.  Abrupt cessation, reduction in dosage, or administration of an opiate antagonist such as naloxone may precipitate withdrawal symptoms.  In patients who have developed tolerance to an opiate agonist, overdosage can still produce respiratory depression and death, and cross-tolerance usually will occur with other agents in the class.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with opiate agonists.  It may be prudent to refrain from dispensing large quantities of medication to these patients.  After prolonged use or if dependency is suspected, withdrawal of opiate therapy should be undertaken gradually using a dosage-tapering schedule.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1594, 0, 'Oliceridine', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1595, 0, 'Oliceridine', 'Hypotension', 'Opiate agonists can induce vasodilation and significant hypotension, particularly when given in high dosages and/or by rapid intravenous administration.  Opiate analgesics cause vasodilatation that may exacerbate hypotension and hypoperfusion and, therefore, are contraindicated in circulatory shock.  At therapeutic analgesic dosages, ambulatory patients are more likely to experience dizziness and hypotension than patients who are confined to bed.  However, orthostatic hypotension may occur in supine patients upon rising.  Therapy with opiate agonists should be administered cautiously and initiated at reduced dosages in patients with hypovolemia, or a predisposition to hypotension.  When given by intramuscular or subcutaneous administration, clinicians should also be aware that impaired perfusion in these patients may prevent complete absorption of the drug.  With repeated injections, an excessive amount may be absorbed suddenly if normal circulation is reestablished.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1596, 0, 'Oliceridine', 'Intracranial Hypertension', 'The hypoventilation associated with administration of opiate agonists, particularly by the intravenous route, can induce cerebral hypoxia and vasodilatation with resultant increase in intracranial pressure.  Opiate agonists should not be used in patients with suspected or known head injury or increased intracranial pressure.  Also, clinicians treating such patients should be aware that opiate agonists may interfere with the evaluation of CNS function, especially with respect to consciousness levels, respiratory status, and pupillary changes.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1597, 0, 'Oliceridine', 'Respiratory Insufficiency', 'Opiate agonists may produce significant central nervous system and respiratory depression of varying duration, particularly when given in high dosages and/or by rapid intravenous administration.  Apnea may result from decreased respiratory drive as well as increased airway resistance, and rigidity of respiratory muscles may occur during rapid IV administration or when these agents are used in the induction of anesthesia.  At therapeutic analgesic dosages, the respiratory effects are usually not clinically important except in patients with preexisting pulmonary impairment.  Therapy with opiate agonists should be avoided or administered with extreme caution and initiated at reduced dosages in patients with severe CNS depression; sleep apnea; hypoxia, anoxia, or hypercapnia; upper airway obstruction; chronic pulmonary insufficiency; a limited ventilatory reserve; or other respiratory disorders.  In the presence of excessive respiratory secretions, the use of opiate agonists may also be problematic because they decrease ciliary activity and reduce the cough reflex.  Caution is also advised in patients who may be at increased risk for respiratory depression, such as comatose patients or those with head injury, intracranial lesions, or intracranial hypertension.  Clinical monitoring of pulmonary function is recommended, and equipment for resuscitation should be immediately available if parenteral or neuraxial routes are used.  Naloxone may be administered to reverse clinically significant respiratory depression, which may be prolonged depending on the opioid agent, cumulative dose, and route of administration.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1598, 0, 'Oliceridine', 'Adrenal Insufficiency', 'Patients with Addison''s disease may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  Conversely, these agents may cause or potentiate adrenal insufficiency.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with adrenocortical insufficiency.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1599, 0, 'Oliceridine', 'Epilepsy', 'Narcotic (opioid) analgesic agents may exacerbate seizures in patients with seizure disorders and, at higher dosages, have been reported to induce seizures in patients without previous history of seizures.  The proconvulsant activity may be the greatest with meperidine, the active metabolite of which is thought to be responsible.  Therapy with opioids should be administered cautiously in patients with or predisposed to seizures.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1600, 0, 'Oliceridine', 'Urinary Retention', 'Narcotic (opioid) analgesic agents may inhibit the urinary voiding reflex and increase the tone of the vesical sphincter in the bladder.  Acute urinary retention requiring catheterization may occur, particularly in patients with prostatic hypertrophy or urethral stricture and in elderly patients.  These agents may also decrease urine production via direct effects on the kidney and central stimulation of the release of vasopressin.  Therapy with opioids should be administered cautiously in patients with or predisposed to urinary retention and/or oliguria.  The effects on smooth muscle tone appear to be the most pronounced with morphine.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1601, 0, 'Omadacycline', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1602, 0, 'Olaparib', 'Neutropenia', 'Olaparib might cause Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML), sometimes with fatal outcomes.  Care should be exercised when using olaparib in patients with a history of previous cancer or bone marrow dysplasia.  Do not start olaparib until patients have recovered from hematological toxicity caused by previous chemotherapy (<= Grade 1).  It is recommended to monitor patients for hematological toxicities at baseline and monthly thereafter for clinically significant changes during treatment.  Interrupt olaparib for prolonged hematological toxicities and monitor blood counts weekly until recovery and discontinue treatment if MDS/AML is confirmed.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1603, 0, 'Olaparib', 'Hepatic Insufficiency', 'Olaparib primarily undergoes hepatic metabolism via CYP450 3A4 and CYP450 3A5; the majority of metabolism is through oxidation with some metabolites undergoing subsequent glucuronide or sulfate conjugation.  No dose adjustment is needed in patients with mild hepatic impairment.  It is recommended to use caution when using olaparib in patients with moderate or severe hepatic impairment as there are no data available.  Close monitoring is recommended.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1604, 0, 'Olaparib', 'Respiration Disorders', 'Pneumonitis, including fatal cases, occurred in <1% of patients treated with olaparib.  It is recommended to interrupt treatment if patients present new or worsening respiratory symptoms such as dyspnea, cough and fever, or a radiological abnormality.  Assess for the source of symptoms and if pneumonitis is confirmed, olaparib should be discontinued and the patient treated appropriately.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1605, 0, 'Olaparib', 'Kidney Diseases', 'In a olaparib renal impairment trial, the mean AUC increased by 24%, and the Cmax increased by 15%, in patients with mild renal impairment.  In patients with moderate renal impairment, the AUC increased by 44% and the Cmax by 26%.  No dose adjustment is needed in patients with mild renal impairment.  The dose of olaparib in patients with moderate renal impairment should be adjusted according to the prescribing information.  It is recommended to monitor for toxicity all patient with renal impairment.  The pharmacokinetics of olaparib have not been evaluated in patients with severe renal impairment or end-stage renal disease.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1606, 0, 'Ondansetron', 'Long QT Syndrome', 'ECG changes including QT interval prolongation have been observed in patients receiving ondansetron.  Additionally, there have been some postmarketing reports of Torsade de Pointes cases.  The use of ondansetron should be avoided in patients with congenital long QT syndrome.  ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, patients with congestive heart failure, bradyarrhythmias, or patients taking other medicines that could lead to QT prolongation.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1607, 0, 'Ondansetron', 'Liver Diseases', 'Ondansetron is extensively metabolized by the liver.  The plasma clearance of ondansetron may be substantially decreased and the half-life prolonged in patients with impaired hepatic function.  During clinical trials in patients receiving concomitant chemotherapy, transient elevations of serum transaminases and isolated cases of jaundice have been reported.  Therapy with ondansetron should be administered cautiously at reduced dosages in patients with liver disease.  The manufacturer recommends a maximum daily dosage of 8 mg in severe hepatic impairment.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1608, 0, 'Opicapone', 'Pheochromocytoma', 'The use of opicapone is contraindicated in patients with pheochromocytoma, paraganglioma, or other catecholamine secreting neoplasms.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1609, 0, 'Opicapone', 'Psychotic Disorders', 'Opicapone may cause impulse control disorders including pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating, and compulsive eating.  Patients with a major psychotic disorder should ordinarily not be treated with this drug because of the risk of exacerbating the psychosis with an increase in central dopaminergic tone.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1610, 0, 'Opicapone', 'Kidney Failure, Chronic', 'The pharmacokinetics of opicapone have not been studied in patients with end stage renal disease.  Caution is advised.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1611, 0, 'Opicapone', 'Hypotension', 'Opicapone may cause orthostatic blood pressure changes including fainting and dizziness and patients should be advised to avoid standing rapidly after sitting or lying down.  Caution is advised in patients with hypotension.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1612, 0, 'Opicapone', 'Liver Failure', 'The mean overall plasma exposure (AUC) of opicapone increased by 84% in patients with moderate (Child-Pugh Class B) liver dysfunction.  A dosage adjustment is required on these patients.  The pharmacokinetics of this drug have not been studied in patients with severe liver dysfunction (Child-Pugh:  C).  Caution is advised.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1613, 0, 'Opicapone', 'Lactose Intolerance', 'Opicapone formulations contain lactose.  Caution is advised if used in patients with lactose intolerance.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1614, 0, 'Oprelvekin', 'Water-Electrolyte Imbalance', 'Oprelvekin causes fluid retention that can result in peripheral edema, dyspnea on exertion, pulmonary edema, atrial arrhythmias, dilution decreases in hemoglobin and hematocrit and changes in serum electrolyte concentrations.  Therapy with oprelvekin should be administered cautiously in patients adversely affected by fluid retention, such as patients with congestive heart failure.  Clinical monitoring of fluid status and electrolyte levels is recommended.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1615, 0, 'Oprelvekin', 'Arrhythmias, Cardiac', 'Transient artrial arrhythmias (fibrillation and flutter) have occurred in approximately 10% of patients receiving oprelvekin.  Cardiac conditions, previous cardiotoxic chemotherapy, or advanced age are considered risk factors for development of oprelvekin- associated arrhythmias.  Therapy with oprelvekin should be administered cautiously in patients with or predisposed to artrial arrhythmias.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1616, 0, 'Oprelvekin', 'Papilledema', 'Papilledema has been reported in 2% of patients receiving oprelvekin.  Therapy with oprelvekin should be administered cautiously in patients with papilledema or CNS tumors as papilledema can be worsened or induced during therapy.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1617, 0, 'Oprelvekin', 'Kidney Diseases', 'Oprelvekin is primarily eliminated by the kidneys and drug exposure was significantly increased in patients with severe renal impairment (CrCl <30 mL/min).  The recommended dose in these patients is 50 mcg/kg once a day.  No significant changes were observed in patients with mild or moderate impairment.  Fluid retention associated with oprelvekin has not been studied in patients with renal impairment, but fluid balance should be carefully monitored in these patients.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1618, 0, 'Opium', 'Gastrointestinal Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the gastrointestinal tract and decrease peristalsis, which can lead to elevated intraluminal pressure, spasm, and constipation following prolonged use.  In patients with severe or acute inflammatory bowel disease, the decrease in colonic motility may induce toxic megacolon.  Therapy with opioids should be administered cautiously in patients with gastrointestinal obstruction, constipation, inflammatory bowel disease, or recent gastrointestinal tract surgery.  Gastrointestinal effects appear to be the most pronounced with morphine.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1619, 0, 'Opium', 'Dysentery', 'Narcotic (opioid) analgesic agents may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella, Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  These agents decrease gastrointestinal motility, which may delay the excretion of infective gastroenteric organisms and/or their toxins.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  Therapy with opioids should be avoided or administered cautiously in patients with infectious diarrhea, particularly that due to pseudomembranous enterocolitis or enterotoxin-producing bacteria or if accompanied by high fever, pus, or blood in the stool.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1620, 0, 'Opium', 'Liver Diseases', 'Narcotic (opioid) analgesic agents are extensively metabolized by the liver, and several of them (e.g., codeine, hydrocodone, meperidine, methadone, morphine, propoxyphene) have active metabolites that are further converted to inactive substances.  The serum concentrations of these agents and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with liver disease.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1621, 0, 'Opium', 'Premature Birth', 'The use of narcotic (opioid) analgesic agents is contraindicated in premature infants.  These agents may cross the immature blood-brain barrier to a greater extent than in adults, resulting in disproportionate respiratory depression.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1622, 0, 'Opium', 'Alcoholic Intoxication', 'The use of opiate agonists is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of opiate agonists may be additive with those of alcohol.  Severe respiratory depression and death may occur.  Therapy with opiate agonists should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1623, 0, 'Opium', 'Substance-Related Disorders', 'Opiate agonists have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop after prolonged use.  Abrupt cessation, reduction in dosage, or administration of an opiate antagonist such as naloxone may precipitate withdrawal symptoms.  In patients who have developed tolerance to an opiate agonist, overdosage can still produce respiratory depression and death, and cross-tolerance usually will occur with other agents in the class.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with opiate agonists.  It may be prudent to refrain from dispensing large quantities of medication to these patients.  After prolonged use or if dependency is suspected, withdrawal of opiate therapy should be undertaken gradually using a dosage-tapering schedule.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1624, 0, 'Opium', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1625, 0, 'Opium', 'Hypotension', 'Opiate agonists can induce vasodilation and significant hypotension, particularly when given in high dosages and/or by rapid intravenous administration.  Opiate analgesics cause vasodilatation that may exacerbate hypotension and hypoperfusion and, therefore, are contraindicated in circulatory shock.  At therapeutic analgesic dosages, ambulatory patients are more likely to experience dizziness and hypotension than patients who are confined to bed.  However, orthostatic hypotension may occur in supine patients upon rising.  Therapy with opiate agonists should be administered cautiously and initiated at reduced dosages in patients with hypovolemia, or a predisposition to hypotension.  When given by intramuscular or subcutaneous administration, clinicians should also be aware that impaired perfusion in these patients may prevent complete absorption of the drug.  With repeated injections, an excessive amount may be absorbed suddenly if normal circulation is reestablished.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1626, 0, 'Opium', 'Intracranial Hypertension', 'The hypoventilation associated with administration of opiate agonists, particularly by the intravenous route, can induce cerebral hypoxia and vasodilatation with resultant increase in intracranial pressure.  Opiate agonists should not be used in patients with suspected or known head injury or increased intracranial pressure.  Also, clinicians treating such patients should be aware that opiate agonists may interfere with the evaluation of CNS function, especially with respect to consciousness levels, respiratory status, and pupillary changes.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1627, 0, 'Opium', 'Respiratory Insufficiency', 'Opiate agonists may produce significant central nervous system and respiratory depression of varying duration, particularly when given in high dosages and/or by rapid intravenous administration.  Apnea may result from decreased respiratory drive as well as increased airway resistance, and rigidity of respiratory muscles may occur during rapid IV administration or when these agents are used in the induction of anesthesia.  At therapeutic analgesic dosages, the respiratory effects are usually not clinically important except in patients with preexisting pulmonary impairment.  Therapy with opiate agonists should be avoided or administered with extreme caution and initiated at reduced dosages in patients with severe CNS depression; sleep apnea; hypoxia, anoxia, or hypercapnia; upper airway obstruction; chronic pulmonary insufficiency; a limited ventilatory reserve; or other respiratory disorders.  In the presence of excessive respiratory secretions, the use of opiate agonists may also be problematic because they decrease ciliary activity and reduce the cough reflex.  Caution is also advised in patients who may be at increased risk for respiratory depression, such as comatose patients or those with head injury, intracranial lesions, or intracranial hypertension.  Clinical monitoring of pulmonary function is recommended, and equipment for resuscitation should be immediately available if parenteral or neuraxial routes are used.  Naloxone may be administered to reverse clinically significant respiratory depression, which may be prolonged depending on the opioid agent, cumulative dose, and route of administration.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1628, 0, 'Opium', 'Adrenal Insufficiency', 'Patients with Addison''s disease may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  Conversely, these agents may cause or potentiate adrenal insufficiency.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with adrenocortical insufficiency.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1629, 0, 'Opium', 'Gallbladder Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the biliary tract, which can lead to spasm and elevated biliary tract pressure, especially in the sphincter of Oddi.  Biliary effects appear to be the most pronounced with morphine, although they do not always occur with therapeutic doses.  Therapy with opioids should be administered cautiously in patients with biliary or gallbladder disease.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1630, 0, 'Opium', 'Hypothyroidism', 'Patients with hypothyroidism may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  These agents may also exacerbate the effects of hypothyroidism such as lethargy, impaired mentation, depression, and constipation.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with uncontrolled hypothyroidism or myxedema.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1631, 0, 'Opium', 'Kidney Diseases', 'Although narcotic (opioid) analgesic agents are generally metabolized by the liver, renal impairment can alter the elimination of these agents and their metabolites (some of which are pharmacologically active), resulting in drug accumulation and increased risk of toxicity.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with significantly impaired renal function.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1632, 0, 'Opium', 'Epilepsy', 'Narcotic (opioid) analgesic agents may exacerbate seizures in patients with seizure disorders and, at higher dosages, have been reported to induce seizures in patients without previous history of seizures.  The proconvulsant activity may be the greatest with meperidine, the active metabolite of which is thought to be responsible.  Therapy with opioids should be administered cautiously in patients with or predisposed to seizures.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1633, 0, 'Opium', 'Urinary Retention', 'Narcotic (opioid) analgesic agents may inhibit the urinary voiding reflex and increase the tone of the vesical sphincter in the bladder.  Acute urinary retention requiring catheterization may occur, particularly in patients with prostatic hypertrophy or urethral stricture and in elderly patients.  These agents may also decrease urine production via direct effects on the kidney and central stimulation of the release of vasopressin.  Therapy with opioids should be administered cautiously in patients with or predisposed to urinary retention and/or oliguria.  The effects on smooth muscle tone appear to be the most pronounced with morphine.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1634, 0, 'Opium', 'Arrhythmias, Cardiac', 'Opiate agonists have cholinergic activity.  Large doses and/or rapid intravenous administration may produce bradycardia and arrhythmia via stimulation of medullary vagal nuclei.  Unlike other agents in the class, meperidine also has anticholinergic activity and may cause either bradycardia or tachycardia.  Therapy with opiate agonists should be administered cautiously in patients with a history of arrhythmias.  Clinical monitoring of cardiovascular status is recommended during therapy.  Bradycardia and other cholinergic effects produced by these agents may be controlled with atropine.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1635, 0, 'Orciprenaline', 'Cardiovascular Diseases', 'Adrenergic bronchodilators can stimulate cardiovascular beta- 1 and beta- 2 receptors, resulting in adverse effects such as tachycardia, palpitation, peripheral vasodilation, blood pressure changes, and ECG changes (e.g., flattening of the T wave; prolongation of the QT interval; ST segment depression).  Direct stimulation of cardiac tissues is mediated by beta- 1 receptors and thus less likely to occur with beta-2-selective agents such as albuterol.  However, beta-2-selectivity is not absolute and can be lost with larger doses.  High dosages of these agents have been associated with precipitation or aggravation of angina, myocardial ischemia, and cardiac arrhythmias.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, and/or underlying cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, or hypertension.  The recommended dosages should not be exceeded.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1636, 0, 'Orciprenaline', 'Diabetes Mellitus', 'Adrenergic bronchodilators may cause increases in blood glucose concentrations.  These effects are usually transient and slight, but may be significant with dosages higher than those normally recommended.  Large doses of IV albuterol (not commercially available in the U.S.) and terbutaline sulfate have been reported to cause exacerbation of preexisting diabetes mellitus and ketoacidosis.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with diabetes mellitus.  Closer monitoring of blood glucose concentrations may be appropriate.  Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1637, 0, 'Orciprenaline', 'Hypokalemia', 'Adrenergic bronchodilators may cause decreases in serum potassium concentrations, primarily when given by nebulization or intravenous administration.  Although this effect is usually transient and does not require supplementation, clinically significant hypokalemia may occur in some patients, with the potential to induce cardiovascular adverse effects.  The relevance of these observations to oral or oral aerosol/powder for inhalation therapy is unknown.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with or predisposed to hypokalemia.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1638, 0, 'Orciprenaline', 'Seizures', 'Adrenergic bronchodilators may cause CNS stimulation.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with seizure disorders.  Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1639, 0, 'Oritavancin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1640, 0, 'Oritavancin', 'Hemorrhage', 'Oritavancin has been shown to artificially prolong prothrombin time (PT) and international normalized ratio (INR) for up to 12 hours, making the monitoring of the anticoagulation effect of warfarin unreliable up to 12 hours after an oritavancin dose.  Oritavancin has no effect on the coagulation system in vivo.  Care should be taken when administering this agent to patients at risk for bleeding and they should be monitored for bleeding if concomitantly receiving warfarin.  It is recommended to consider a non-phospholipid dependent coagulation test such as a Factor Xa (chromogenic) assay or an alternative anticoagulant not requiring aPTT monitoring for those patients requiring aPTT monitoring within 5 days of oritavancin dosing.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1641, 0, 'Oritavancin', 'Hepatic Insufficiency', 'No dosage adjustment of oritavancin is needed in patients with mild or moderate hepatic impairment.  Care should be taken when administering oritavancin to patients with severe hepatic impairment as the pharmacokinetics of this agent have not been studied.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1642, 0, 'Oritavancin', 'Kidney Diseases', 'No dosage adjustment of oritavancin is needed in patients with mild or moderate renal impairment.  Care should be taken when administering oritavancin to patients with severe renal impairment as the pharmacokinetics of this agent have not been evaluated.  Oritavancin is not removed from blood by hemodialysis.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1643, 0, 'Atracurium', 'Premature Birth', 'Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative.  Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  Thus, single-dose formulations should always be used in infants whenever possible.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered.  The level at which toxicity may occur is unknown.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1644, 0, 'Atracurium', 'Burns', 'Patients with burns may develop resistance to non-depolarizing neuromuscular blocking agents.  These patients may experience a shorter duration of action and/or require higher dosages of the drugs.  The extent of altered response depends on the duration since and the size of the burn.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1645, 0, 'Atracurium', 'Hypersensitivity', 'Some neuromuscular blocking agents stimulate the release of histamine, which can cause wheezing, bronchospasm, increased bronchial secretions, hypotension, tachycardia, and circulatory collapse.  Hypotension may also occur due to ganglionic blockade or as a complication of positive pressure respiration.  Tubocurarine appears to be the most potent inducer of histamine, followed by metocurine (no longer commercially available in the U.S.) and succinylcholine.  Other agents with varying but lesser degrees of histamine-releasing properties include atracurium, mivacurium, and pancuronium (at excessive dosages).  Therapy with these neuromuscular blocking agents should be administered cautiously in patients with clinically significant cardiovascular disease and/or a history of asthma or severe allergic reactions.  Certain agents may prolong the QTc interval, especially during general anesthesia in pediatric patients.  The initial dosage and rate of administration may need to be reduced, and hemodynamic and respiratory status carefully monitored.  Neuromuscular blocking agents that appear to have little or no histamine-inducing effects include cisatracurium, doxacurium, pipecuronium, rocuronium, and vecuronium.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1646, 0, 'Atracurium', 'Myasthenia Gravis', 'The use of neuromuscular blocking agents may cause prolonged respiratory paralysis.  Therapy with neuromuscular blocking agents should be administered cautiously in patients with myasthenia gravis.  Use of a peripheral nerve stimulator may be helpful in evaluating the level of neuromuscular blockade.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1647, 0, 'Atracurium', 'Paresis', 'Patients with hemiparesis or paraparesis may require higher dosages of non-depolarizing neuromuscular blocking agents in the affected limbs.  Neuromuscular monitoring should be performed on a non-paretic limb to avoid inaccurate dosing.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1648, 0, 'Atracurium', 'Respiratory Insufficiency', 'Neuromuscular blocking agents can cause respiratory depression and paralysis.  Therapy with neuromuscular blocking agents should be administered cautiously in patients with pulmonary impairment.  Treatment of respiratory paralysis consists of positive-pressure artificial respiration with oxygen and maintenance of a patent airway until the recovery of normal respiration is assured.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1649, 0, 'Orphenadrine', 'Anticholinergic Syndrome', 'Orphenadrine has mild anticholinergic activity, to which elderly patients are particularly sensitive.  The manufacturer considers the use of orphenadrine to be contraindicated in patients with glaucoma, pyloric or duodenal obstruction, achalasia, prostatic hypertrophy, bladder neck obstruction, or myasthenia gravis.  Orphenadrine should be used cautiously in other conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention and gastrointestinal obstructive disorders.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1650, 0, 'Oseltamivir', 'Hepatic Insufficiency', 'The safety and pharmacokinetics of oseltamivir in patients with severe hepatic impairment have not been evaluated.  No dose adjustment is required in patients with mild to moderate hepatic impairment.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1651, 0, 'Oseltamivir', 'Kidney Diseases', 'Dose adjustment of oseltamivir treatment is recommended for patients with a serum creatinine clearance between 10 and 30 mL/min.  No recommended dosing regimens are available for patients with end-stage disease undergoing routine hemodialysis or continuous peritoneal dialysis treatment.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1652, 0, 'Orlistat', 'Malabsorption Syndromes', 'The use of orlistat is contraindicated in patients with chronic malabsorption syndrome or cholestasis.  Orlistat can worsen the malabsorption in these conditions by reversibly inhibiting lipases that are necessary for the hydrolysis of triglycerides into absorbable free fatty acids and monoglycerides.  At the recommended therapeutic dosage of 120 mg three times a day, orlistat inhibits dietary fat absorption by approximately 30%.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1653, 0, 'Orlistat', 'Diabetes Mellitus, Type 2', 'Obese, type 2 diabetic patients who achieve weight loss may demonstrate improved metabolic control of their disease as a result of their reduced weight.  Therefore, patients with type 2 diabetes mellitus should be monitored during weight-reduction therapy (or therapy that may be expected to induce significant weight loss as a secondary effect) for hypoglycemia and reduced need for oral hypoglycemic medication or insulin, and the dosages of these agents adjusted accordingly.  Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitation.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1654, 0, 'Orlistat', 'Fat Soluble Vitamin Deficiency', 'At the recommended therapeutic dosage of 120 mg three times a day, orlistat inhibits dietary fat absorption by approximately 30% and has been shown to reduce the absorption of some fat-soluble vitamins and beta-carotene.  Therapy with orlistat should be administered cautiously in patients with preexisting deficiency of one or more fat-soluble vitamins (A, D, E and K).  Ideally, the deficiency should be corrected prior to initiation of therapy.  A multivitamin supplement containing fat-soluble vitamins is recommended during therapy, best taken once a day at least 2 hours before or after the administration of orlistat.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1655, 0, 'Orlistat', 'Nephrolithiasis', 'Following treatment with orlistat, some patients may develop increased levels of urinary oxalate as a result of fat malabsorption.  Therapy with orlistat should be administered cautiously in patients with a history of hyperoxaluria or calcium oxalate nephrolithiasis.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1656, 0, 'Ospemifene', 'Breast Neoplasms', 'Ospemifene has not been adequately studied in women with breast cancer, therefore should not be used in women with known, suspected or with a history of breast cancer.  Additionally, ospemifene is contraindicated in the presence of any known or suspected estrogen-dependent neoplasia.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1657, 0, 'Ospemifene', 'Cardiovascular disease', 'There is a reported increase of stroke and deep vein thrombosis (DVT) in postmenopausal women receiving oral conjugated estrogens.  Ospemifene should be prescribed for the shortest duration consistent with treatment goals, weighting risks and benefits for each woman.  Ospemifene is contraindicated in women with active DVT, pulmonary embolism, active arterial thromboembolic disease (such as stroke or myocardial infarctions), or a history of any of these conditions.  Other risk factors for cardiovascular disorders and/or venous thromboembolism such as hypertension, diabetes, smoking, hypercholesterolemia, obesity, lupus erythematosus (in personal or family history), should be evaluated and managed appropriately.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1658, 0, 'Ospemifene', 'Uterine Hemorrhage', 'The use of ospemifene is contraindicated in women with any undiagnosed abnormal genital bleeding.  There is an increased risk of endometrial hyperplasia and endometrial cancer in patients using estrogens.  Adequate diagnostic measures should be undertaken to rule out malignancy in any postmenopausal woman with undiagnosed persistent or recurring abnormal genital bleeding.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1659, 0, 'Ospemifene', 'Liver Failure', 'Ospemifene should not be used in women with severe hepatic impairment, as the pharmacokinetics have not been studied in these patients.  No clinically important differences were observed in women with mild to moderate hepatic impairment when compared to healthy women, therefore no dose adjustment is needed in these patients.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1660, 0, 'Osilodrostat', 'Hepatic Insufficiency', 'Dosage adjustment of osilodrostat is required for patients with moderate to severe liver dysfunction.  The recommended starting dose for patients with moderate liver dysfunction is 1 mg orally twice a day, and for patients with severe liver dysfunction is 1 mg orally once a day in the evening.  No dose adjustment is required in patients with mild liver dysfunction.  More frequent monitoring of adrenal function may be needed during dose titration in all patients with liver dysfunction.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1661, 0, 'Osilodrostat', 'Kidney Diseases', 'No dosage adjustment of osilodrostat is required for patients with impaired renal function.  However, in patients with moderate to severe renal dysfunction, urinary free cortisol (UFC) levels should be interpreted with caution due to reduced UFC excretion.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1662, 0, 'Osilodrostat', 'Arrhythmias, Cardiac', 'The use of osilodrostat is associated with a dose-dependent QT interval prolongation, which may cause cardiac arrhythmias.  It is recommended to perform an ECG to obtain a baseline QTc interval measurement before starting therapy and to monitor for an effect on the QTc interval thereafter.  Temporary discontinuation of osilodrostat should be considered in the case of an increase in QTc interval greater than 480 milliseconds.  Hypokalemia and hypomagnesemia should be corrected before initiating treatment and monitored regularly during treatment.  Electrolyte abnormalities should be corrected if indicated.  Care should be exercised when using this agent in patients with risk factors for QT prolongation and more frequent ECG monitoring should be considered.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1663, 0, 'Osilodrostat', 'Adrenal Insufficiency', 'Osilodrostat lowers cortisol levels and can lead to hypocortisolism and sometimes life-threatening adrenal insufficiency.  Patients should be evaluated for precipitating causes of hypocortisolism.  Serum/plasma cortisol, 24-hour urine free cortisol, and patient''s signs/symptoms should be monitored periodically during treatment.  Osilodrostat should be decreased or temporarily discontinued if urine free cortisol levels fall below the target range, there is a rapid decrease in cortisol levels, and/or patients report hypocortisolism symptoms.  Therapy should be stopped and exogenous glucocorticoid replacement therapy should be administered if serum/plasma cortisol levels are below the target range and patients have symptoms of adrenal insufficiency.  Osilodrostat should be restarted at a lower dose when urine free cortisol and serum/plasma cortisol levels are within the target range, and/or patient symptoms have resolved.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1664, 0, 'Oxacillin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1665, 0, 'Oxacillin', 'Hematologic Diseases', 'The use of penicillinase-resistant penicillins has been associated with adverse hematologic effects, including neutropenia, leukopenia, granulocytopenia and thrombocytopenia, particularly when given in high parenteral dosages.  Agranulocytosis and prolonged bleeding time have been reported rarely.  Therapy with penicillinase-resistant penicillins should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow depression, and hematopoietic function should be monitored.  Blood counts with differential should be performed prior to initiation of therapy and 1 to 3 times weekly during therapy.  Hematologic abnormalities are generally reversible and resolve within several days to two weeks following discontinuation of therapy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1666, 0, 'Oxacillin', 'Kidney Diseases', 'Oxacillin is partially converted by the liver to active and inactive metabolites, and both parent drug and metabolites are eliminated by the kidney.  The serum concentrations of oxacillin and its metabolites may be increased and the half-lives prolonged in patients with significantly impaired renal function.  In general, dosage adjustments are not necessary in either renal or hepatic impairment, but the lower range of the usual recommended dosage may be appropriate in patients with severe renal impairment (CrCl < 10 mL/min).  Renal and liver function tests should be performed periodically during prolonged therapy.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1667, 0, 'Oxacillin', 'Water-Electrolyte Imbalance', 'Each gram of parenteral oxacillin sodium contains approximately 64 to 71 mg (2.8 to 3.1 mEq) of sodium and is buffered with 40 mg of dibasic sodium phosphate.  Each 250 mg capsule of oxacillin sodium contains approximately 16 mg (0.7 mEq) of sodium, and each teaspoonful of the 250 mg/5 mL oral solution contains approximately 18 mg (0.8 mEq) of sodium.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  In addition, hypokalemia has been reported rarely during therapy with the penicillinase-resistant penicillins, which may be particularly important to bear in mind when treating patients with low potassium reserves or fluid and electrolyte imbalance.  Clinical monitoring of electrolytes is recommended if these agents are used for prolonged periods.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1668, 0, 'Oxandrolone', 'Prostatic Neoplasms', 'The use of androgenic anabolic steroids is contraindicated for male patients with carcinoma of the breast or prostate.  Circulating androgens can be converted in peripheral tissues to estrogens and dihydrotestosterone, which may act as promoters of tumor growth in the breast and prostate, respectively.  Likewise, androgenic agents may cause enlargement of the prostate and should be used cautiously in patients with or predisposed to prostatic hypertrophy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1669, 0, 'Oxandrolone', 'Water-Electrolyte Imbalance', 'Androgenic anabolic steroids may cause sodium and water retention, particularly when given in high dosages or for prolonged periods.  Therapy with these agents should be administered cautiously in patients who have preexisting problems with fluid overload or are at risk for developing edema.  The manufacturers consider the use of androgenic agents to be contraindicated in patients with severe cardiac, renal and/or hepatic dysfunction.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1670, 0, 'Oxandrolone', 'Breast Neoplasms', 'When treated with androgenic anabolic steroids, patients with metastatic breast cancer may develop hypercalcemia due to osteolysis.  Frequent determination of urine and serum calcium levels is recommended during therapy with androgenic agents.  If hypercalcemia occurs, therapy should be stopped.  The development of hypercalcemia may indicate progression of metastases to the bone.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1671, 0, 'Oxandrolone', 'Hyperlipoproteinemias', 'Androgenic anabolic steroids may adversely affect serum lipids, including lowering HDL and elevating LDL levels.  These changes can be marked, particularly with the 17-alpha-alkyl derivatives (i.e., fluoxymesterone, methyltestosterone, oxandrolone, oxymetholone, and stanozolol), and may significantly impact the risk of atherosclerosis and coronary artery disease.  Patients with preexisting hyperlipoproteinemia may require closer monitoring during therapy with androgenic agents, and adjustments made accordingly in their lipid-lowering regimen.  Androgen therapy should be administered cautiously in patients with coronary artery disease or a history of ischemic heart disease.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1672, 0, 'Oxandrolone', 'Liver Diseases', 'The use of androgenic anabolic steroids may be associated with development of cholestatic hepatitis and jaundice.  Other, more serious hepatotoxicities such as peliosis hepatis and hepatocellular neoplasms are rare but may occur with prolonged use or high dosages.  These latter toxicities may be fatal and often not recognized until they become life-threatening.  Patients with preexisting liver diseases should be monitored more closely during therapy with anabolic steroids if they are used.  If liver function declines or toxicity occurs, therapy should be withdrawn and the cause investigated.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1673, 0, 'Oxandrolone', 'Polycythemia', 'Androgenic anabolic steroids may cause polycythemia when given in high dosages or for prolonged periods.  Patients with preexisting polycythemia may experience worsening of their condition.  Frequent monitoring of clinical status and hemoglobin and hematocrit levels is recommended if androgen therapy is administered to these patients.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1674, 0, 'Oxandrolone', 'Blood Coagulation Disorders', 'Androgenic anabolic steroids may cause suppression of clotting factors II, V, VII, and X, and an increase in prothrombin time.  Androgen therapy should be administered cautiously in patients with bleeding disorders.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1675, 0, 'Oxandrolone', 'Diabetes Mellitus', 'The metabolic effects of androgenic anabolic steroids may lower blood glucose.  Decreased glucose tolerance and increased insulin resistance have also been reported.  Patients with diabetes mellitus should be monitored more closely during therapy with androgenic agents, and their antidiabetic regimen adjusted accordingly.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1676, 0, 'Oxandrolone', 'Hypercalcemia', 'Androgenic anabolic steroids decrease urinary excretion of calcium, which may result in hypercalcemia.  Therapy with androgenic agents should be administered cautiously in patients with hypercalcemia, disorders of bone metabolism such as hyperparathyroidism, or renal dysfunction.  Some manufacturers consider the use of androgenic anabolic steroids to be contraindicated in patients with hypercalcemia.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1677, 0, 'Oxandrolone', 'Thyroid Diseases', 'When androgenic anabolic steroids are used in patients with thyroid disorders, clinicians should be aware that these agents may affect thyroid function tests.  Specifically, thyroid-binding globulin levels may be decreased, resulting in lower total T4 serum levels and increased resin uptake of T3 and T4.  Free thyroid hormone levels remain unchanged, however.', '1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1678, 0, 'Osimertinib', 'Cardiomyopathies', 'Cardiomyopathy was observed in clinical trials of certain EGFR inhibitors.  Assess Left Ventricular Ejection Fraction (LVEF) by echocardiogram or multigated acquisition (MUGA) scan before initiation of these agents and then at 3 month intervals while on treatment.  Caution is recommended when prescribing these agents to patients with conditions that could impair left ventricular function and it is recommended to withhold treatment with these agents if ejection fraction drops below the established lower limit of normal.  For symptomatic congestive heart failure or persistent, asymptomatic LV dysfunction that does not resolve within 4 weeks, permanently discontinue these agents.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1679, 0, 'Osimertinib', 'Stevens-Johnson Syndrome', 'Cutaneous reactions, in some cases severe, have been reported with the use of EGFR inhibitors.  Monitor patients who develop dermatologic or soft tissue toxicities while receiving these agents for the development of inflammatory or infectious sequelae.  It is recommended to withhold treatment, and appropriate measures should be instituted as appropriate or discontinue the use of these agents for dermatologic or soft tissue toxicity associated with severe or life-threatening inflammatory or infectious complications.  Advise patients to wear sunscreen and hats and limit sun exposure while receiving therapy with these agents as exposure to sunlight can exacerbate dermatologic toxicities.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1680, 0, 'Osimertinib', 'Eye Diseases', 'Some epidermal growth factor receptor (EGFR) inhibitors should be administered cautiously in patients with ocular disorders such as primary keratitis, ulcerative keratitis, or conjunctivitis.  It is recommended to interrupt or discontinue treatment with these agents if patients present with acute or worsening ocular disorders.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1681, 0, 'Osimertinib', 'Lung Diseases', 'The use of certain EGFR inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1682, 0, 'Osimertinib', 'Long QT Syndrome', 'QT prolongation was observed in patients treated with certain EGFR inhibitors.  These agents should be administered with caution in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval.  Serum electrolytes should be corrected prior to initiating therapy with these agents.  Periodic monitoring of ECGs and electrolytes is recommended in these patients.  Permanently discontinue the use of these agents in patients who develop QTc interval prolongation with signs/symptoms of life-threatening arrhythmia.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1683, 0, 'Osimertinib', 'Hepatic Insufficiency', 'No formal pharmacokinetic studies of osimertinib have been conducted in patients with renal or hepatic impairment.  Based on population pharmacokinetic (PK) analysis of osimertinib, no dose adjustment is recommended in patients with mild (CrCl 60-89 mL/min) or moderate (CrCl 30-59 mL/min) renal impairment, or mild hepatic impairment (total bilirubin <ULN and AST between 1 to 1.5 times the ULN or total bilirubin between 1.0 to 1.5 times ULN and any AST ).  There are no data on the pharmacokinetics of osimertinib in patients with severe renal impairment (CrCl less than 30 mL/min) or with moderate to severe hepatic impairment (moderate:  total bilirubin between 1.5 to 3.0 times ULN and any AST, and severe:  total bilirubin between 3.0-10 times ULN and any AST).  Close monitoring is recommended for these patients.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1684, 0, 'Oxaprozin', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1685, 0, 'Oxaprozin', 'Water-Electrolyte Imbalance', 'Fluid retention and edema have been reported in association with the use of nonsteroidal anti-inflammatory drugs (NSAIDs).  Therapy with NSAIDs should be administered cautiously in patients with preexisting fluid retention, hypertension, or a history of heart failure.  Blood pressure and cardiovascular status should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1686, 0, 'Oxaprozin', 'Peptic Ulcer', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal.  These serious adverse events can develop at any time, with or without warning symptoms.  Only 1 in 5 patients who develop a serious upper GI side effect on NSAIDs is symptomatic.  NSAIDs should be used with caution in patients with history of peptic ulcer disease and/or GI bleeding, as these patients had a greater than 10-fold increased risk for developing a GI bleed compared to patients without these risk factors.  Caution is also advised if NSAIDs are prescribed to patients with other factors that increase risk of GI bleeding, such as:  prolonged NSAID therapy; concomitant use of oral corticosteroids, antiplatelet agents (e.g., aspirin), anticoagulants, selective serotonin reuptake inhibitors; alcohol use; smoking; history of gastrointestinal surgery or anastomosis, older age; poor general health status; and advanced liver disease and/or coagulopathy.  Particular vigilance is necessary when treating elderly or debilitated patients since most postmarketing reports of fatal GI events occurred in these patients.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1687, 0, 'Oxaprozin', 'Exanthema', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious skin adverse reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, and exfoliative dermatitis), which can be fatal.  These serious events may occur without warning.  Patients should be advised to discontinue the NSAID and seek medical attention promptly at the first sign of skin rash or any other sign of hypersensitivity.  NSAIDs are contraindicated in patients with previous serious skin reactions to these drugs.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1688, 0, 'Oxaprozin', 'Kidney Diseases', 'Long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) has resulted in renal papillary necrosis and other renal injury.  Renal toxicity has been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion:  in such patients, NSAIDs may cause a dose-dependent reduction in prostaglandin synthesis and, secondarily, in renal blood flow, which may precipitate overt renal decompensation.  Patients at greatest risk for this reaction include the elderly, those with impaired renal function, dehydration, hypovolemia, heart failure, or liver dysfunction, and those taking diuretics, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers; discontinuation of NSAID therapy will usually lead to recovery to the pretreatment state.  No information is available regarding use NSAIDs in patients with advanced renal disease; the renal effects of NSAIDs may hasten the progression of renal dysfunction in patients with preexisting renal disease.  Volume status should be corrected in dehydrated or hypovolemic patients prior to initiating treatment.  Renal function should be monitored during therapy in patients with renal or liver dysfunction, heart failure, dehydration, or hypovolemia.  NSAIDs should be avoided in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function; if an NSAID is used in such patients, they should be monitored for signs of worsening renal function.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1689, 0, 'Oxaprozin', 'Thrombosis', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.  This risk may occur early in treatment and may increase with duration of use.  Clinical trials of several cyclooxygenase-2 (COX-2) selective and nonselective NSAIDs of up to 3 years duration have supported this increased risk.  It is unclear from available data if the risk for cardiovascular thrombotic events is similar for all NSAIDs.  Therapy with NSAIDs should be administered cautiously in patients with a history of cardiovascular or cerebrovascular disease.  Patients should be treated with the lowest effective dosage for the shortest duration necessary.  Appropriate antiplatelet therapy should be administered to patients requiring cardioprotection; however, there is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious cardiovascular thrombotic events associated with NSAID use, while the risk of serious gastrointestinal events is increased.  Physicians and patients should remain alert for the development of adverse cardiovascular events throughout the entire duration of therapy, even without prior cardiovascular symptoms.  Patients should be advised to promptly seek medical attention if they experience symptoms of cardiovascular thrombotic events (including chest pain, shortness of breath, weakness, or slurring of speech).NSAIDs are contraindicated in the setting of coronary artery bypass graft (CABG) surgery.  Two large clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10 to 14 days following CABG surgery found an increased incidence of myocardial infarction and stroke.The use of NSAIDs should be avoided in patients with a recent myocardial infarction unless the benefits are expected to outweigh the risk of recurrent cardiovascular thrombotic events.  If an NSAID is used in patients with a recent myocardial infarction, they should be monitored for signs of cardiac ischemia.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1690, 0, 'Oxaprozin', 'Anemia', 'Anemia has been reported in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  This may be due to fluid retention, occult/gross blood loss, or an incompletely described effect on erythropoiesis.  Hemoglobin or hematocrit should be monitored in patients with any signs/symptoms of anemia or blood loss, especially during long-term therapy.  NSAIDs may increase risk of bleeding events; comorbid conditions (e.g., coagulation disorders; concomitant use of warfarin/other anticoagulants, antiplatelet agents, serotonin/serotonin norepinephrine reuptake inhibitors) may increase this risk, and patients with these conditions should be monitored for signs of bleeding.  Therapy with NSAIDs should be administered cautiously in patients with or predisposed to anemia.  Clinical monitoring of hematopoietic function may be appropriate, particularly during chronic therapy.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1691, 0, 'Oxaprozin', 'Heart Failure', 'Fluid retention and edema have been observed in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs), including some topical formulations.  These drugs should be avoided in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure.  If an NSAID is used in patients with severe heart failure, they should be monitored for signs of worsening heart failure.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1692, 0, 'Oxaprozin', 'Liver Diseases', 'Borderline elevations of 1 or more liver tests may occur in up to 15% of patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  These laboratory abnormalities may progress, remain unchanged, or regress with continuing therapy.  Elevations of ALT or AST (at least 3 times the upper limit of normal) have been reported in about 1% of patients in clinical trials.  In addition, rare (sometimes fatal) cases of severe hepatotoxicity, including liver necrosis, hepatic failure, jaundice, and fulminant hepatitis have been reported.  Therapy with NSAIDs should be administered cautiously in patients with preexisting liver disease.  Periodic monitoring of liver function is recommended during prolonged therapy.  NSAIDs are also highly protein-bound and some are extensively metabolized by the liver.  Metabolic activity and/or plasma protein binding may be altered in patients with hepatic impairment.  A dosage reduction may be required in some cases.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1693, 0, 'Oxaprozin', 'Hyperkalemia', 'Increases in serum potassium concentration (including hyperkalemia) have been reported with use of nonsteroidal anti-inflammatory drugs (NSAIDs), even in some patients without renal impairment.  In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.  Caution is advised in patients with hyperkalemia.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1694, 0, 'Oxaprozin', 'Hypertension', 'Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events.  NSAIDs should be used with caution in patients with hypertension.  Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1695, 0, 'Oxaprozin', 'Blood Platelet Disorders', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) reversibly inhibit platelet adhesion and aggregation and may prolong bleeding time in some patients.  With the exception of aspirin, the platelet effects seen with most NSAIDs at usual recommended dosages are generally slight and of relatively short duration but may be more pronounced in patients with underlying hemostatic abnormalities.  Thrombocytopenia has also been reported rarely during NSAID use.  Therapy with NSAIDs should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  NSAIDs that selectively inhibit cyclooxygenase-2 (i.e., COX-2 inhibitors) do not appear to affect platelet function or bleeding time at indicated dosages and may be preferable if risk of bleeding is a concern.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1696, 0, 'Atropine', 'Diabetic Neuropathies', 'Agents with anticholinergic activity can exacerbate many of the manifestations of autonomic neuropathy, including tachycardia, anhidrosis, bladder atony, obstipation, dry mouth and eyes, cycloplegia and blurring of vision, and sexual impotence in males.  Therapy with antimuscarinic agents and higher dosages of antispasmodic agents (e.g., dicyclomine or oxybutynin) should be administered cautiously in patients with autonomic neuropathy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1697, 0, 'Atropine', 'Intestinal Obstruction', 'Anticholinergics are contraindicated in patients with obstructive diseases such as achalasia, esophageal stricture or stenosis, pyloroduodenal stenosis, stenosing peptic ulcer, pyloric obstruction, and paralytic ileus.  Anticholinergics may further suppress intestinal motility with resultant precipitation or aggravation of toxic megacolon.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1698, 0, 'Atropine', 'Glaucoma', 'Anticholinergic agents are contraindicated in patients with primary glaucoma, a tendency toward glaucoma (narrow anterior chamber angle), or adhesions (synechiae) between the iris and lens, as well as for the elderly and others in whom undiagnosed glaucoma or excessive pressure in the eye may be present.  Because anticholinergics cause mydriasis, they may exacerbate these conditions.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1699, 0, 'Atropine', 'Urinary Bladder Neck Obstruction', 'In general, the use of anticholinergic agents is contraindicated in patients with urinary retention and bladder neck obstruction caused by prostatic hypertrophy.  Dysuria may occur and may require catheterization.  Also, anticholinergic drugs may aggravate partial obstructive uropathy.  Caution is advised even when using agents with mild to moderate anticholinergic activity, particularly in elderly patients.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1700, 0, 'Atropine', 'Lung Diseases', 'The use of systemic anticholinergics is contraindicated in the treatment of lower respiratory tract symptoms including asthma.  Muscarinic receptor antagonists reduce bronchial secretions, which can result in decreased fluidity and increased thickening of secretions.  However, ipratropium does not produce these effects and can be used safely in treating asthma.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1701, 0, 'Atropine', 'Myasthenia Gravis', 'Because antimuscarinic agents have anticholinergic effects, they are contraindicated in patients with myasthenia gravis.  Their use may be appropriate to reduce adverse muscarinic effects caused by an anticholinesterase agent.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1702, 0, 'Atropine', 'Dysentery', 'The use of drugs with antiperistaltic activity (primarily antidiarrheal and antimuscarinic agents, but also antispasmodic agents such as dicyclomine or oxybutynin at high dosages) is contraindicated in patients with diarrhea due to pseudomembranous enterocolitis or enterotoxin-producing bacteria.  These drugs may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella and Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  In general, because antiperistaltic agents decrease gastrointestinal motility, they may delay the excretion of infective gastroenteric organisms or toxins and should be used cautiously in patients with any infectious diarrhea, particularly if accompanied by high fever or pus or blood in the stool.  Some cough and cold and other combination products may occasionally include antimuscarinic agents for their drying effects and may, therefore, require careful selection when necessary.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1703, 0, 'Atropine', 'Heart Diseases', 'Anticholinergics block vagal inhibition of the SA nodal pacemaker.  Therapy with anticholinergics should be administered cautiously to patients with tachycardia, congestive heart failure, or coronary artery disease.  Premature ventricular depolarization, ventricular tachycardia, and fibrillation associated with anticholinergics are rare.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1704, 0, 'Atropine', 'Tachycardia', 'Anticholinergics block vagal inhibition of the SA nodal pacemaker.  Therapy with anticholinergics should be administered cautiously in patients with tachycardia, congestive heart failure, or coronary artery disease.  Premature ventricular depolarization or ventricular tachycardia or fibrillation associated with anticholinergics is rare.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1705, 0, 'Atropine', 'Coronary Artery Disease', 'Antimuscarinic agents block vagal inhibition of the SA nodal pacemaker.  These agents should be administered cautiously in patients with tachycardia, congestive heart failure, or coronary artery disease.  Premature ventricular depolarization or ventricular tachycardia or fibrillation associated with antimuscarinic drugs is rare.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1706, 0, 'Atropine', 'Stomach Ulcer', 'Antimuscarinic agents may cause a delay in gastric emptying and possibly antral stasis in patients with gastric ulcer.  Therapy with antimuscarinic agents should be administered cautiously to patients with gastric ulcer.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1707, 0, 'Atropine', 'Gastroesophageal Reflux', 'Antimuscarinic agents decrease gastric motility and relax the lower esophageal sphincter which promotes gastric retention and can aggravate reflux.  These drugs should be administered cautiously in patients with gastroesophageal reflux or hiatal hernia associated with reflux esophagitis.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1708, 0, 'Atropine', 'Colitis, Ulcerative', 'Antimuscarinic agents may suppress intestinal motility and produce paralytic ileus with resultant precipitation of toxic megacolon.  These drugs should be administered cautiously to patients with ulcerative colitis.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1709, 0, 'Atropine', 'Liver Diseases', 'Atropine-like agents undergo significant hepatic metabolism.  Therapy with atropine-like agents should be administered cautiously to patients with liver disease.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1710, 0, 'Atropine', 'Renal Insufficiency', 'Atropine-like agents are primarily eliminated by the kidney.  Therapy with atropine-like agents should be administered cautiously to patients with renal disease.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1711, 0, 'Atropine', 'Hypertension', 'Cardiovascular effects of anticholinergics may exacerbate hypertension.  Therapy with anticholinergic agents should be administered cautiously in patients with hypertension.', '1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1712, 0, 'Atropine', 'Hyperthyroidism', 'In general, agents with anticholinergic activity may exacerbate hyperthyroidism.  Therapy with anticholinergics should be administered cautiously in patients with hyperthyroidism.  Thyroid levels should be monitored if usage is prolonged.', '1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1713, 0, 'Atropine', 'Diarrhea', 'Diarrhea may be a symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy.  Antimuscarinic agents may further aggravate the diarrhea.  Therefore, these drugs should be administered cautiously in patients with diarrhea.', '1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1714, 0, 'Atropine', 'Fever', 'Atropine-like agents may increase the risk of hyperthermia in patients with fever by producing anhidrosis.  Therapy with atropine-like agents should be administered cautiously in febrile patients.', '1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1715, 0, 'Oxaliplatin', 'Arrhythmias, Cardiac', 'The use of oxaliplatin has been associated with QT prolongation, and ventricular arrhythmias including fatal Torsade de Pointes.  Therapy with oxaliplatin should be administered cautiously in patients with congestive heart failure, bradyarrhythmias, and electrolyte abnormalities.  Correct hypokalemia or hypomagnesemia prior to initiating oxaliplatin and monitor these electrolytes periodically during therapy.  Avoid oxaliplatin in patients with congenital long QT syndrome.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1716, 0, 'Oxaliplatin', 'Lung Diseases', 'Oxaliplatin has been associated with pulmonary fibrosis (<1% of study patients), which may be fatal.  Caution should be exercised when administering oxaliplatin in patients with compromised pulmonary function.  Patients should be instructed to immediately report symptoms of unexplained respiratory symptoms such as non-productive cough, dyspnea, crackles, or radiological pulmonary infiltrates.  Close clinical monitoring of pulmonary function is recommended and oxaliplatin should be discontinued until further pulmonary investigation excludes interstitial lung disease or pulmonary fibrosis.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1717, 0, 'Oxaliplatin', 'Neurotoxicity Syndromes', 'Oxaliplatin for injection is associated with two types of neuropathy.  An acute, reversible, primarily peripheral, sensory neuropathy that is of early onset, occurring within hours or one to two days of dosing, that resolves within 14 days, and that frequently recurs with further dosing and a persistent (>14 days), primarily peripheral, sensory neuropathy that is usually characterized by paresthesias, dysesthesias, hypoesthesias, but may also include deficits in proprioception that can interfere with daily activities (e.g., writing, buttoning, swallowing, and difficulty walking from impaired proprioception).  Ice (mucositis prophylaxis) should be avoided during the infusion of oxaliplatin for Injection because cold temperature can exacerbate acute neurological symptoms.  Therapy with oxaliplatin should be administered cautiously in patients with or predisposed to neurologic dysfunction.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1718, 0, 'Oxaliplatin', 'Neutropenia', 'The use of oxaliplatin for injection and 5-fluorouracil/leucovorin has been associated with sepsis, neutropenic sepsis and septic shock with fatal outcomes.  Therapy with oxaliplatin should be administered cautiously in patients predisposed to neutropenia.  Patients should be warned to report any febrile illness.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1719, 0, 'Oxaliplatin', 'Kidney Diseases', 'The major route of platinum elimination is renal excretion.  The exposure (AUC) of unbound platinum in plasma ultrafiltrate tends to increase in renally impaired patients.  The starting dose of oxaliplatin should be reduced in patients with severe renal impairment (creatinine clearance < 30 mL/min).  Caution and close monitoring should be exercised when oxaliplatin is administered to patients with renal impairment.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1720, 0, 'Oxaliplatin', 'Rhabdomyolysis', 'Rhabdomyolysis, including fatal cases, has been reported during the administration of oxaliplatin.  Therapy with oxaliplatin should be administered cautiously in patients with or predisposed to myopathy.  Clinical monitoring is recommended during therapy with oxaliplatin and discontinuation of therapy if any signs or symptoms of rhabdomyolysis occur.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1721, 0, 'Oxaliplatin', 'Thrombocytopenia', 'Thrombocytopenia was frequently reported with the combination of oxaliplatin and infusional 5-FU/LV.  Therapy with oxaliplatin should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or irradiation, whose marrow function is recovering from previous cytotoxic therapy, or in patients with compromised renal function.  Patients should be instructed to immediately report any signs or symptoms suggesting bleeding such as petechia, purpura, epistaxis, hemoptysis, hematuria, and melena.  Therapy with oxaliplatin should be administered cautiously in patients with compromised bone marrow reserve.  Close clinical monitoring of hematopoietic function is recommended.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1722, 0, 'Oxazepam', 'Alcoholic Intoxication', 'The use of benzodiazepines with alcohol is not recommended.  Patients with acute alcohol intoxication exhibit depressed vital signs.  The central nervous system depressant effects of benzodiazepines may be additive with those of alcohol, and severe respiratory depression and death may occur.  Therapy with benzodiazepines should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1723, 0, 'Oxazepam', 'Glaucoma, Angle-Closure', 'The manufacturers consider the use of benzodiazepines to be contraindicated in patients with acute angle-closure glaucoma or untreated open-angle glaucoma.  These agents do not possess anticholinergic activity but have very rarely been associated with increased intraocular pressure.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1724, 0, 'Oxazepam', 'Substance-Related Disorders', 'Benzodiazepines have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use and/or excessive dosages.  However, abrupt cessation following continual use of as few as 6 weeks at therapeutic levels has occasionally precipitated withdrawal symptoms.  Addiction- prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance when treated with benzodiazepines.  It may be prudent to refrain from dispensing large quantities of medication to these patients.  After prolonged use or if dependency is suspected, withdrawal of benzodiazepine therapy should be undertaken gradually using a dosage- tapering schedule.  If withdrawal symptoms occur, temporary reinstitution of benzodiazepines may be necessary.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1725, 0, 'Oxazepam', 'Psychotic Disorders', 'The use of some benzodiazepines is not recommended for depressive neuroses and psychotic reactions.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1726, 0, 'Oxazepam', 'Liver Diseases', 'Benzodiazepines are metabolized by the liver, and the metabolites are excreted in the urine.  Chlordiazepoxide, clorazepate, diazepam, flurazepam and quazepam undergo oxidative N-dealkylation to active metabolites that are substantially longer-acting than the parent compound.  These metabolites then undergo further biotransformation to pharmacologically inactive products before excretion by the kidney.  Therapy with benzodiazepines should be administered cautiously at lower initial dosages in patients with impaired renal and/or hepatic function.  Agents that are converted to weakly active, short-acting, or inactive metabolites may be preferable in hepatic impairment.  Lorazepam, oxazepam and temazepam are conjugated to inactive metabolites, while alprazolam, estazolam and triazolam undergo hydroxylation to weakly active or inactive metabolites.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1727, 0, 'Oxazepam', 'Respiratory Insufficiency', 'Benzodiazepines may cause respiratory depression and apnea, usually when given in high dosages and/or by intravenous administration.  However, some patients may be susceptible at commonly used dosages, including the elderly, debilitated or severely ill patients, those receiving other CNS depressants, and those with limited ventilatory reserve, chronic pulmonary insufficiency or other respiratory disorders.  Therapy with benzodiazepines should be administered cautiously in these patients.  Appropriate monitoring and individualization of dosage are particularly important, and equipment for resuscitation should be immediately available if the parenteral route is used.  Benzodiazepines, especially injectable formulations, should generally be avoided in patients with sleep apnea, severe respiratory insufficiency, or hypoxia.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1728, 0, 'Oxazepam', 'Seizures', 'The use of benzodiazepines in patients with seizure disorders may increase the incidence or precipitate the onset of generalized tonic-clonic seizures (grand mal).  Appropriate anticonvulsant medication might need to be initiated or the dosage increased.  Abrupt cessation of benzodiazepine therapy may precipitate seizures and other withdrawal symptoms, particularly after prolonged use and/or excessive dosages.  Status epilepticus may occur in patients with a history of seizures withdrawn rapidly from benzodiazepine therapy.  Following chronic administration, cessation of benzodiazepine therapy should occur gradually with incrementally reduced dosages.  Patients should be advised not to discontinue medication without first consulting with the physician.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1729, 0, 'Oxazepam', 'Depressive Disorder', 'Benzodiazepines depress the central nervous system and may cause or exacerbate mental depression and cause suicidal behavior and ideation.  Episodes of mania and hypomania have also been reported in depressed patients treated with some of these agents.  Therapy with benzodiazepines should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1730, 0, 'Oxazepam', 'Obesity', 'The plasma half-lives of benzodiazepines may be prolonged in obese patients, presumably due to increased distribution into fat.  Marked increases in distribution (> 100%) have been reported for diazepam and midazolam, and moderate increases (25% to 100%) for alprazolam, lorazepam, and oxazepam.  Therapy with benzodiazepines should be administered cautiously in obese patients, with careful monitoring of CNS status.  Longer dosing intervals may be appropriate.  When dosing by weight, loading doses should be based on actual body weight, while maintenance dose should be based on ideal body weight to avoid toxicity.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1731, 0, 'Oxazepam', 'Hypotension', 'Although hypotension has occurred only rarely, Oxazepam should be used with caution in patients predisposed to hypotension, in whom a drop in blood pressure might lead to cardiac complications.  This is particularly true in the elderly patients.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1732, 0, 'Oxcarbazepine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1733, 0, 'Oxcarbazepine', 'Liver Diseases', 'Most anticonvulsants are primarily metabolized by the liver.  Metabolic activity may be decreased in patients with liver disease, resulting in elevated drug levels and increased risk of toxicity.  Therapy with anticonvulsants should be administered cautiously in patients with mild and moderate liver impairment.  Therapy with these drugs is mostly not recommended in patients with severe liver impairment.  Caution is also advised when treating patients with a history of liver disease, since the use of some anticonvulsants has been associated with hepatotoxicity.  Baseline and periodic evaluation of liver function is recommended.  Therapy should be discontinued and not readministered if evidence of liver damage is observed and felt to be drug-related.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1734, 0, 'Oxcarbazepine', 'Kidney Diseases', 'Most anticonvulsants are primarily excreted by the kidney.  The plasma clearance may be decreased and the half-life prolonged in patients with impaired renal function.  Therapy with anticonvulsants should be administered cautiously in patients with significant renal dysfunction.  In most cases it is recommended to adjust the dosage in patients with CrCl <50 mL/min to half the usual starting dose and then increase slowly to achieve the desired clinical response.  The renal function should be monitored regularly in patients receiving therapy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1735, 0, 'Oxcarbazepine', 'Hyponatremia', 'Some anticonvulsants can cause clinically significant hyponatremia (Na < 125 mmol/L).  Therapy with these drugs should be administered cautiously in patients with conditions predisposing to hyponatremia, such as SIADH, use of diuretics or drugs associated with inappropriate antidiuretic hormone secretion, adrenal insufficiency, hypothyroidism, primary polydipsia, and edema (e.g., due to liver cirrhosis, congestive heart failure, or nephrotic syndrome).  Serum sodium levels should be monitored during maintenance therapy, and patients should be monitored for signs and symptoms possibly indicating hyponatremia such as nausea, malaise, headache, lethargy, confusion, obtundation, and increase in seizure frequency or severity.  If hyponatremia occurs, conservative measures such as fluid restriction, a reduction in dosage, or discontinuation of therapy will usually suffice.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1736, 0, 'Oxcarbazepine', 'Arrhythmias, Cardiac', 'Aromatic antiepileptic drugs such as phenytoin, carbamazepine, and oxcarbazepine, inhibit voltage- gated sodium channels and reduce membrane excitability in neurons and muscle and can be associated with cardiovascular effects.  Individual agents have demonstrated AV heart block, including second and third-degree block following treatment.  This occurred generally, but not solely in patients with underlying EKG abnormalities or risk factors for conduction abnormalities.  Therapy with these agents should be considered and administered cautiously in patients with a history of cardiovascular disease and conduction abnormalities.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1737, 0, 'Oxcarbazepine', 'Hematologic Diseases', 'Rare events of pancytopenia, leukopenia, and agranulocytosis have been reported in patients treated with oxcarbazepine during postmarketing observations.  Discontinuation of the drug should be considered if any evidence of these hematologic events develop.  Therapy with oxcarbazepine should be administered with caution in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts, including platelets and possibly reticulocytes and serum iron, should be performed prior to initiating therapy and regularly during therapy.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1738, 0, 'Oxcarbazepine', 'Hypothyroidism', 'Decreased values for thyroid function tests, especially T4 have been observed with the administration of oxcarbazepine.  This should be taken into account in patients with thyroid disorders.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1739, 0, 'Atropine (ophthalmic)', 'Glaucoma', 'Anticholinergic agents are contraindicated in patients with primary glaucoma, a tendency toward glaucoma (narrow anterior chamber angle), or adhesions (synechiae) between the iris and lens, as well as for the elderly and others in whom undiagnosed glaucoma or excessive pressure in the eye may be present.  Because anticholinergics cause mydriasis, they may exacerbate these conditions.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1740, 0, 'Atropine (ophthalmic)', 'Hypertension', 'Cardiovascular effects of anticholinergics may exacerbate hypertension.  Therapy with anticholinergic agents should be administered cautiously in patients with hypertension.', '1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1741, 0, 'Oxymorphone', 'Gastrointestinal Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the gastrointestinal tract and decrease peristalsis, which can lead to elevated intraluminal pressure, spasm, and constipation following prolonged use.  In patients with severe or acute inflammatory bowel disease, the decrease in colonic motility may induce toxic megacolon.  Therapy with opioids should be administered cautiously in patients with gastrointestinal obstruction, constipation, inflammatory bowel disease, or recent gastrointestinal tract surgery.  Gastrointestinal effects appear to be the most pronounced with morphine.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1742, 0, 'Oxymorphone', 'Dysentery', 'Narcotic (opioid) analgesic agents may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella, Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  These agents decrease gastrointestinal motility, which may delay the excretion of infective gastroenteric organisms and/or their toxins.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  Therapy with opioids should be avoided or administered cautiously in patients with infectious diarrhea, particularly that due to pseudomembranous enterocolitis or enterotoxin-producing bacteria or if accompanied by high fever, pus, or blood in the stool.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1743, 0, 'Oxymorphone', 'Liver Diseases', 'Narcotic (opioid) analgesic agents are extensively metabolized by the liver, and several of them (e.g., codeine, hydrocodone, meperidine, methadone, morphine, propoxyphene) have active metabolites that are further converted to inactive substances.  The serum concentrations of these agents and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with liver disease.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1744, 0, 'Oxymorphone', 'Premature Birth', 'The use of narcotic (opioid) analgesic agents is contraindicated in premature infants.  These agents may cross the immature blood-brain barrier to a greater extent than in adults, resulting in disproportionate respiratory depression.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1745, 0, 'Oxymorphone', 'Alcoholic Intoxication', 'The use of opiate agonists is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of opiate agonists may be additive with those of alcohol.  Severe respiratory depression and death may occur.  Therapy with opiate agonists should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1746, 0, 'Oxymorphone', 'Substance-Related Disorders', 'Opiate agonists have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop after prolonged use.  Abrupt cessation, reduction in dosage, or administration of an opiate antagonist such as naloxone may precipitate withdrawal symptoms.  In patients who have developed tolerance to an opiate agonist, overdosage can still produce respiratory depression and death, and cross-tolerance usually will occur with other agents in the class.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with opiate agonists.  It may be prudent to refrain from dispensing large quantities of medication to these patients.  After prolonged use or if dependency is suspected, withdrawal of opiate therapy should be undertaken gradually using a dosage-tapering schedule.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1747, 0, 'Oxymorphone', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1748, 0, 'Oxymorphone', 'Hypotension', 'Opiate agonists can induce vasodilation and significant hypotension, particularly when given in high dosages and/or by rapid intravenous administration.  Opiate analgesics cause vasodilatation that may exacerbate hypotension and hypoperfusion and, therefore, are contraindicated in circulatory shock.  At therapeutic analgesic dosages, ambulatory patients are more likely to experience dizziness and hypotension than patients who are confined to bed.  However, orthostatic hypotension may occur in supine patients upon rising.  Therapy with opiate agonists should be administered cautiously and initiated at reduced dosages in patients with hypovolemia, or a predisposition to hypotension.  When given by intramuscular or subcutaneous administration, clinicians should also be aware that impaired perfusion in these patients may prevent complete absorption of the drug.  With repeated injections, an excessive amount may be absorbed suddenly if normal circulation is reestablished.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1749, 0, 'Oxymorphone', 'Intracranial Hypertension', 'The hypoventilation associated with administration of opiate agonists, particularly by the intravenous route, can induce cerebral hypoxia and vasodilatation with resultant increase in intracranial pressure.  Opiate agonists should not be used in patients with suspected or known head injury or increased intracranial pressure.  Also, clinicians treating such patients should be aware that opiate agonists may interfere with the evaluation of CNS function, especially with respect to consciousness levels, respiratory status, and pupillary changes.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1750, 0, 'Oxymorphone', 'Respiratory Insufficiency', 'Opiate agonists may produce significant central nervous system and respiratory depression of varying duration, particularly when given in high dosages and/or by rapid intravenous administration.  Apnea may result from decreased respiratory drive as well as increased airway resistance, and rigidity of respiratory muscles may occur during rapid IV administration or when these agents are used in the induction of anesthesia.  At therapeutic analgesic dosages, the respiratory effects are usually not clinically important except in patients with preexisting pulmonary impairment.  Therapy with opiate agonists should be avoided or administered with extreme caution and initiated at reduced dosages in patients with severe CNS depression; sleep apnea; hypoxia, anoxia, or hypercapnia; upper airway obstruction; chronic pulmonary insufficiency; a limited ventilatory reserve; or other respiratory disorders.  In the presence of excessive respiratory secretions, the use of opiate agonists may also be problematic because they decrease ciliary activity and reduce the cough reflex.  Caution is also advised in patients who may be at increased risk for respiratory depression, such as comatose patients or those with head injury, intracranial lesions, or intracranial hypertension.  Clinical monitoring of pulmonary function is recommended, and equipment for resuscitation should be immediately available if parenteral or neuraxial routes are used.  Naloxone may be administered to reverse clinically significant respiratory depression, which may be prolonged depending on the opioid agent, cumulative dose, and route of administration.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1751, 0, 'Oxymorphone', 'Adrenal Insufficiency', 'Patients with Addison''s disease may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  Conversely, these agents may cause or potentiate adrenal insufficiency.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with adrenocortical insufficiency.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1752, 0, 'Oxymorphone', 'Gallbladder Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the biliary tract, which can lead to spasm and elevated biliary tract pressure, especially in the sphincter of Oddi.  Biliary effects appear to be the most pronounced with morphine, although they do not always occur with therapeutic doses.  Therapy with opioids should be administered cautiously in patients with biliary or gallbladder disease.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1753, 0, 'Oxymorphone', 'Hypothyroidism', 'Patients with hypothyroidism may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  These agents may also exacerbate the effects of hypothyroidism such as lethargy, impaired mentation, depression, and constipation.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with uncontrolled hypothyroidism or myxedema.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1754, 0, 'Oxymorphone', 'Kidney Diseases', 'Although narcotic (opioid) analgesic agents are generally metabolized by the liver, renal impairment can alter the elimination of these agents and their metabolites (some of which are pharmacologically active), resulting in drug accumulation and increased risk of toxicity.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with significantly impaired renal function.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1755, 0, 'Oxymorphone', 'Epilepsy', 'Narcotic (opioid) analgesic agents may exacerbate seizures in patients with seizure disorders and, at higher dosages, have been reported to induce seizures in patients without previous history of seizures.  The proconvulsant activity may be the greatest with meperidine, the active metabolite of which is thought to be responsible.  Therapy with opioids should be administered cautiously in patients with or predisposed to seizures.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1756, 0, 'Oxymorphone', 'Urinary Retention', 'Narcotic (opioid) analgesic agents may inhibit the urinary voiding reflex and increase the tone of the vesical sphincter in the bladder.  Acute urinary retention requiring catheterization may occur, particularly in patients with prostatic hypertrophy or urethral stricture and in elderly patients.  These agents may also decrease urine production via direct effects on the kidney and central stimulation of the release of vasopressin.  Therapy with opioids should be administered cautiously in patients with or predisposed to urinary retention and/or oliguria.  The effects on smooth muscle tone appear to be the most pronounced with morphine.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1757, 0, 'Oxymorphone', 'Arrhythmias, Cardiac', 'Opiate agonists have cholinergic activity.  Large doses and/or rapid intravenous administration may produce bradycardia and arrhythmia via stimulation of medullary vagal nuclei.  Unlike other agents in the class, meperidine also has anticholinergic activity and may cause either bradycardia or tachycardia.  Therapy with opiate agonists should be administered cautiously in patients with a history of arrhythmias.  Clinical monitoring of cardiovascular status is recommended during therapy.  Bradycardia and other cholinergic effects produced by these agents may be controlled with atropine.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1758, 0, 'Oxymetazoline (nasal)', 'Prostatic Hyperplasia', 'Topically applied sympathomimetic agents are systemically absorbed, with the potential for producing clinically significant systemic effects, particularly during prolonged or indiscriminate use.  In patients with prostate enlargement, urinary difficulty may develop or worsen due to smooth muscle contraction in the bladder neck via stimulation of alpha-1 adrenergic receptors.  Therapy with topical sympathomimetic agents should be administered cautiously in patients with hypertrophy or neoplasm of the prostate.  It is important that the recommended dosages of the individual products not be exceeded.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1759, 0, 'Oxymetazoline (nasal)', 'Cardiovascular Diseases', 'Topically applied sympathomimetic agents are systemically absorbed, with the potential for producing clinically significant systemic effects, particularly during prolonged or indiscriminate use.  In cardiac tissues, these agents may produce positive chronotropic and inotropic effects via stimulation of beta-1 adrenergic receptors.  Cardiac output, oxygen consumption, and the work of the heart may be increased.  In the peripheral vasculature, vasoconstriction may occur via stimulation of alpha-1 adrenergic receptors.  Palpitations, tachycardia, arrhythmia, hypertension, reflex bradycardia, and coronary occlusion have been reported rarely during the use of ophthalmic and nasal sympathomimetic agents, but may be more likely if the corneal epithelium is damaged or if an excessive amount of drug is swallowed during nasal administration.  Therapy with topical sympathomimetic agents should be administered cautiously in patients with corneal abrasion, sensitivity to sympathomimetic amines, hyperthyroidism, or underlying cardiovascular or cerebrovascular disorders, especially coronary insufficiency, cardiac arrhythmia, or hypertension.  The potent ophthalmic formulations (e.g., phenylephrine 2.5% or 10%) that are used for diagnostic and pre-surgical purposes should not be used in such patients.  For other preparations, it is important that the recommended dosages of the individual products not be exceeded.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1760, 0, 'Oxymetazoline (nasal)', 'Diabetes Mellitus', 'Topically applied sympathomimetic agents are systemically absorbed, particularly during prolonged or indiscriminate use.  Slight increases in blood glucose concentrations may occur with the use of these drugs.  Therapy with topical sympathomimetic agents should be administered cautiously in patients with diabetes mellitus.  Closer monitoring of blood glucose concentrations may be appropriate.  It is important that the recommended dosages of the individual products not be exceeded.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1761, 0, 'Ozanimod', 'Cardiovascular Diseases', 'Ozanimod is contraindicated in patients who have had a recent myocardial infarction, those with unstable angina, stroke, transient ischemic attack, decompensated heart failure with hospitalization, or Class III/IV heart failure, a presence of Mobitz Type II 2nd degree or 3rd degree AV block, sick sinus syndrome, or sino-atrial block, unless the patient has a pacemaker, severe untreated sleep apnea or those patients being treated with monoamine oxidase inhibitor drugs.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1762, 0, 'Ozanimod', 'Cardiac Conduction System Disease', 'The use of ozanimod may result in a transient decrease in heart rate and atrioventricular conduction delays upon starting treatment.  It is recommended to follow an up-titration scheme to reach the maintenance dosage.  Initiation of ozanimod without titration may result in greater decreases in heart rate.  If treatment with ozanimod is considered, advice from a cardiologist should be sought for those individuals at risk of cardiovascular effects, particularly conduction delays.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1763, 0, 'Ozanimod', 'Hypertension', 'The use of ozanimod may result in increased blood pressure.  Care should be exercised when using this drug in hypertensive patients and those at risk for hypertension.  It is recommended to monitor blood pressure during treatment and manage it according to clinical practices.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1764, 0, 'Ozanimod', 'Infections', 'Ozanimod may increase the risk of infections and some serious infections with opportunistic pathogens including viruses have been reported.  Because of reversible sequestration of lymphocytes in lymphoid tissues, this drug causes a mean reduction in peripheral blood lymphocyte count to approximately 45% of baseline values.  Prior to treatment, a recent CBC (i.e., within 6 months or after discontinuation of prior therapy), including lymphocyte count must be available.  It is recommended to delay treatment initiation in patients with an active infection until complete resolution.  Consider withholding or discontinuing treatment if a patient develops a serious infection, and reassess the benefits and risks prior to reinitiating therapy.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1765, 0, 'Ozanimod', 'Liver Diseases', 'The use of ozanimod may result in elevations of aminotransferases.  The use of ozanimod in patients with hepatic impairment is not recommended.  While on treatment with this drug, if a patient develop symptoms suggestive of hepatic dysfunction, such as unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, or jaundice and/or dark urine, should have hepatic enzymes checked, and ozanimod should be discontinued if significant liver injury is confirmed.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1766, 0, 'Ozanimod', 'Respiratory Insufficiency', 'The use of ozanimod may result in a dose-dependent reduction in absolute forced expiratory volume over 1 second (FEV1) and may manifest as early as 3 months after treatment initiation.  Care should be exercised when using this drug in patients with respiratory complications.  It is recommended to perform spirometric evaluation of respiratory function during therapy if clinically appropriate.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1767, 0, 'Ozanimod', 'Brain Diseases', 'Rare cases of posterior reversible encephalopathy syndrome (PRES) have been reported in patients receiving a sphingosine 1-phosphate receptor modulator.  It is recommended to promptly schedule a complete physical and neurological examination and should consider an MRI, if a patient develops any unexpected neurological or psychiatric symptoms/signs, any symptom/sign suggestive of an increase of intracranial pressure, or accelerated neurological deterioration.  Delay in diagnosis and treatment may lead to permanent neurological sequelae.  Exercise care when using this agent in patients with a history of ischemic stroke or cerebral hemorrhage.  Treatment should be discontinued if PRES is suspected.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1768, 0, 'Ozanimod', 'Macular Edema', 'Macular edema has been reported with the use of sphingosine 1-phosphate (S1P) receptor modulators.  Care should be exercised when using these drugs in patients with a history of uveitis and patients with diabetes mellitus as these patients are at increased risk for macular edema.  Before starting treatment with these agents, an ophthalmic evaluation of the fundus, including the macula, is recommended in all patients and at any time if vision change is reported during treatment.  Patients with a history of uveitis and patients with diabetes mellitus should have regular follow-up examinations of the fundus, including the macula during treatment.  Continuation of therapy in patients with macular edema has not been evaluated, therefore, a decision on whether or not to discontinue treatment needs to take into account the potential benefits and risks for the individual patients.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1769, 0, 'Ozanimod', 'Multiple Sclerosis', 'Rare cases of severe exacerbation of multiple sclerosis (MS), including disease rebound, have been reported after discontinuation of sphingosine 1-phosphate receptor modulator in MS treated patients.  The possibility of severe exacerbation of disease should be considered after stopping treatment with these agents.  Patients should be observed for a severe increase in disability upon discontinuation and appropriate treatment should be instituted, as required.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1770, 0, 'Palbociclib', 'Lung Diseases', 'The use of certain multikinase inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.  Immediately withhold treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue therapy if no other potential causes of ILD/pneumonitis have been identified.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1771, 0, 'Palbociclib', 'Hepatic Insufficiency', 'Based on a population pharmacokinetic analysis with palbociclib mild hepatic impairment had no effect on the exposure of palbociclib.  Close monitoring is recommended when using this agent in patients with moderate or severe hepatic impairment as the pharmacokinetics of palbociclib have not been studied in these patients.  Dose modification of concomitant medications may be needed based of hepatic impairment.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1772, 0, 'Palbociclib', 'Neutropenia', 'The use of palbociclib may cause neutropenia, including febrile neutropenia and neutropenic sepsis.  It is recommended to monitor complete blood counts prior to starting treatment and at the beginning of each therapy cycle with palbociclib, as well as on Day 15 of the first 2 cycles, and as clinically indicated thereafter.  Dose interruption, dose reduction, or delay in starting treatment cycles is recommended for patients who develop Grade 3 or 4 neutropenia.  Care and close monitoring is recommended, in particular for any episodes of fever.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1773, 0, 'Palbociclib', 'Premenopausal', 'Pre/perimenopausal women treated with the combination palbociclib plus fulvestrant therapy should be treated with luteinizing hormone-releasing hormone (LHRH) agonists according to current clinical practice standards.  Care and close monitoring is recommended.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1774, 0, 'Palbociclib', 'Kidney Diseases', 'Based on a population pharmacokinetic analysis with palbociclib mild and moderate renal impairment had no effect on the exposure of palbociclib.  Close monitoring is recommended when using this agent in patients with severe renal impairment as the pharmacokinetics of palbociclib in these patients have not been studied.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1775, 0, 'Paclitaxel (protein-bound)', 'Cardiac Conduction System Disease', 'Severe conduction abnormalities, some requiring pacemaker placement, have been reported during paclitaxel therapy.  Therapy with paclitaxel should be administered cautiously in patients with or predisposed to conduction disorders.  Clinical monitoring of cardiac function is recommended during subsequent paclitaxel therapy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1776, 0, 'Paclitaxel (protein-bound)', 'Liver Diseases', 'Paclitaxel is extensively metabolized by the liver.  Patients with moderate to severe hepatic impairment may be at increased risk for hepatotoxicity.  Additionally, myelotoxicity of paclitaxel may be exacerbated in patients with serum total bilirubin >2 times ULN.  Therapy with paclitaxel should be administered cautiously and at a reduced dosage in patients with compromised hepatic function.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1777, 0, 'Paclitaxel (protein-bound)', 'Bone Marrow Failure Disorders', 'Paclitaxel induces dose-dependent myelosuppression, primarily affecting neutrophils.  Anemia characterized as a red blood cell count <11 g/dl has been reported in 78% of patients administered paclitaxel.  Thrombocytopenia is uncommon and rarely severe.  Therapy with paclitaxel should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld when neutrophil counts fall below 1500/mm3 and/or platelet counts fall below 100,000/mm3.  Paclitaxel injection should not be used in patients with solid tumors with baseline neutrophil counts less than 1500/mm3 or in patients with AIDS-related Kaposi''s sarcoma with baseline neutrophil counts of less than 1000/mm3.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1778, 0, 'Paclitaxel (protein-bound)', 'Peripheral Nervous System Diseases', 'Dose-dependent peripheral neuropathy has been reported in 60% of patients during paclitaxel therapy.  Severe peripheral neuropathy is rare and requires a 20% reduction in dosage of paclitaxel.  Therapy with paclitaxel should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1779, 0, 'Oxytetracycline', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1780, 0, 'Oxytetracycline', 'Diseases requiring hemodialysis', 'Oxytetracycline is partially removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1781, 0, 'Oxytetracycline', 'Liver Diseases', 'The use of tetracyclines has rarely been associated with hepatotoxicity.  Histologic fatty changes of the liver, elevated liver enzymes, and jaundice have been reported, primarily in patients treated with large doses of intravenous tetracycline hydrochloride (no longer available in the U.S.) but also in patients receiving high oral doses of these drugs.  Therapy with tetracyclines should be administered cautiously in patients with preexisting liver disease or biliary obstruction.  Reduced dosages may be appropriate, particularly with minocycline and doxycycline, since the former is metabolized by the liver and the latter undergoes enterohepatic recycling.  Liver function tests are recommended prior to and during therapy, and the concomitant use of other potentially hepatotoxic drugs should be avoided.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1782, 0, 'Oxytetracycline', 'Kidney Diseases', 'Tetracyclines (except doxycycline) are eliminated by the kidney to various extent.  Patients with renal impairment may be at greater risk for tetracycline-associated hepatic and/or renal toxicity (increased BUN with consequent azotemia, hyperphosphatemia, and acidosis) due to decreased drug clearance.  Therapy with tetracyclines should be administered cautiously at reduced dosages in patients with renal impairment.  Clinical monitoring of renal and liver function is recommended, and serum tetracycline levels may be necessary during prolonged therapy.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1783, 0, 'Oxytetracycline', 'Esophageal Diseases', 'The use of oral tetracycline capsules and tablets has been associated with esophageal irritation and ulceration in patients who ingested the drug without sufficient fluid shortly before bedtime.  Therapy with solid formulations of tetracyclines should preferably be avoided in patients with esophageal obstruction, compression or dyskinesia.  If the drugs are used, patients should be advised not to take the medication just before retiring and to drink fluids liberally.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1784, 0, 'Oxybutynin', 'Diabetic Neuropathies', 'Agents with anticholinergic activity can exacerbate many of the manifestations of autonomic neuropathy, including tachycardia, anhidrosis, bladder atony, obstipation, dry mouth and eyes, cycloplegia and blurring of vision, and sexual impotence in males.  Therapy with antimuscarinic agents and higher dosages of antispasmodic agents (e.g., dicyclomine or oxybutynin) should be administered cautiously in patients with autonomic neuropathy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1785, 0, 'Oxybutynin', 'Dysentery', 'The use of drugs with antiperistaltic activity (primarily antidiarrheal and antimuscarinic agents, but also antispasmodic agents such as dicyclomine or oxybutynin at high dosages) is contraindicated in patients with diarrhea due to pseudomembranous enterocolitis or enterotoxin-producing bacteria.  These drugs may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella and Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  In general, because antiperistaltic agents decrease gastrointestinal motility, they may delay the excretion of infective gastroenteric organisms or toxins and should be used cautiously in patients with any infectious diarrhea, particularly if accompanied by high fever or pus or blood in the stool.  Some cough and cold and other combination products may occasionally include antimuscarinic agents for their drying effects and may, therefore, require careful selection when necessary.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1786, 0, 'Oxybutynin', 'Glaucoma, Angle-Closure', 'The use of oxybutynin is contraindicated in patients with uncontrolled angle-closure (narrow angle) or narrow anterior chamber glaucoma.  Oxybutynin exerts anticholinergic activity (1/5 that of atropine) and can result in increased intraocular pressure and loss of accommodation.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1787, 0, 'Oxybutynin', 'Intestinal Obstruction', 'The use of oxybutynin is contraindicated in patients with GI obstruction, ileus, atony, megacolon, toxic megacolon associated with ulcerative colitis, severe colitis, and obstructive uropathy.  Oxybutynin exerts direct antispasmodic effects on smooth muscles and possesses anticholinergic activity (1/5 that of atropine).', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1788, 0, 'Oxybutynin', 'Myasthenia Gravis', 'The use of oxybutynin is contraindicated in patients with myasthenia gravis.  Oxybutynin exerts direct antispasmodic effects on smooth muscle and inhibits the muscarinic action of acetylcholine on smooth muscle (1/5 the anticholinergic activity of atropine).', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1789, 0, 'Oxybutynin', 'Parkinson Disease', 'Oxybutynin is associated with anticholinergic central nervous system (CNS) effects.  If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered.  Oxybutynin should be used with caution in patients with Parkinson''s disease and in patients with preexisting dementia treated with cholinesterase inhibitors due to the risk of aggravation of symptoms.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1790, 0, 'Oxytocin', 'Vascular Diseases', 'Hypertensive events, subarachnoid hemorrhage, and arrhythmias have occurred during oxytocin therapy.  Oxytocin possesses presser activity.  Caution is advised in patients with uncontrolled hypertension or cerebrovascular dysfunction.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1791, 0, 'Oxytocin', 'Edema', 'Volume overload can occur during administration of oxytocin.  Oxytocin possess antidiuretic properties.  Consideration should, therefore, be given to the possibility of volume overload and water intoxication, particularly when oxytocin is administered continuously by infusion and the patient is receiving fluids by mouth.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1792, 0, 'Oxymetholone', 'Prostatic Neoplasms', 'The use of androgenic anabolic steroids is contraindicated for male patients with carcinoma of the breast or prostate.  Circulating androgens can be converted in peripheral tissues to estrogens and dihydrotestosterone, which may act as promoters of tumor growth in the breast and prostate, respectively.  Likewise, androgenic agents may cause enlargement of the prostate and should be used cautiously in patients with or predisposed to prostatic hypertrophy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1793, 0, 'Oxymetholone', 'Water-Electrolyte Imbalance', 'Androgenic anabolic steroids may cause sodium and water retention, particularly when given in high dosages or for prolonged periods.  Therapy with these agents should be administered cautiously in patients who have preexisting problems with fluid overload or are at risk for developing edema.  The manufacturers consider the use of androgenic agents to be contraindicated in patients with severe cardiac, renal and/or hepatic dysfunction.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1794, 0, 'Oxymetholone', 'Breast Neoplasms', 'When treated with androgenic anabolic steroids, patients with metastatic breast cancer may develop hypercalcemia due to osteolysis.  Frequent determination of urine and serum calcium levels is recommended during therapy with androgenic agents.  If hypercalcemia occurs, therapy should be stopped.  The development of hypercalcemia may indicate progression of metastases to the bone.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1795, 0, 'Oxymetholone', 'Hyperlipoproteinemias', 'Androgenic anabolic steroids may adversely affect serum lipids, including lowering HDL and elevating LDL levels.  These changes can be marked, particularly with the 17-alpha-alkyl derivatives (i.e., fluoxymesterone, methyltestosterone, oxandrolone, oxymetholone, and stanozolol), and may significantly impact the risk of atherosclerosis and coronary artery disease.  Patients with preexisting hyperlipoproteinemia may require closer monitoring during therapy with androgenic agents, and adjustments made accordingly in their lipid-lowering regimen.  Androgen therapy should be administered cautiously in patients with coronary artery disease or a history of ischemic heart disease.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1796, 0, 'Oxymetholone', 'Liver Diseases', 'The use of androgenic anabolic steroids may be associated with development of cholestatic hepatitis and jaundice.  Other, more serious hepatotoxicities such as peliosis hepatis and hepatocellular neoplasms are rare but may occur with prolonged use or high dosages.  These latter toxicities may be fatal and often not recognized until they become life-threatening.  Patients with preexisting liver diseases should be monitored more closely during therapy with anabolic steroids if they are used.  If liver function declines or toxicity occurs, therapy should be withdrawn and the cause investigated.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1797, 0, 'Oxymetholone', 'Polycythemia', 'Androgenic anabolic steroids may cause polycythemia when given in high dosages or for prolonged periods.  Patients with preexisting polycythemia may experience worsening of their condition.  Frequent monitoring of clinical status and hemoglobin and hematocrit levels is recommended if androgen therapy is administered to these patients.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1798, 0, 'Oxymetholone', 'Blood Coagulation Disorders', 'Androgenic anabolic steroids may cause suppression of clotting factors II, V, VII, and X, and an increase in prothrombin time.  Androgen therapy should be administered cautiously in patients with bleeding disorders.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1799, 0, 'Oxymetholone', 'Diabetes Mellitus', 'The metabolic effects of androgenic anabolic steroids may lower blood glucose.  Decreased glucose tolerance and increased insulin resistance have also been reported.  Patients with diabetes mellitus should be monitored more closely during therapy with androgenic agents, and their antidiabetic regimen adjusted accordingly.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1800, 0, 'Oxymetholone', 'Hypercalcemia', 'Androgenic anabolic steroids decrease urinary excretion of calcium, which may result in hypercalcemia.  Therapy with androgenic agents should be administered cautiously in patients with hypercalcemia, disorders of bone metabolism such as hyperparathyroidism, or renal dysfunction.  Some manufacturers consider the use of androgenic anabolic steroids to be contraindicated in patients with hypercalcemia.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1801, 0, 'Oxymetholone', 'Thyroid Diseases', 'When androgenic anabolic steroids are used in patients with thyroid disorders, clinicians should be aware that these agents may affect thyroid function tests.  Specifically, thyroid-binding globulin levels may be decreased, resulting in lower total T4 serum levels and increased resin uptake of T3 and T4.  Free thyroid hormone levels remain unchanged, however.', '1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1802, 0, 'Paliperidone', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1803, 0, 'Paliperidone', 'Long QT Syndrome', 'Some atypical antipsychotic agents can prolong the QTc interval of the electrocardiogram in a dose-dependent manner.  Electrolyte disturbances such as hypokalemia and hypomagnesemia may augment the prolongation effect of these agents on the QT interval and should be corrected prior to institution of therapy.  In addition, patients who experience frequent, severe, or prolonged diarrhea may be subject to electrolyte losses and should be followed closely and managed accordingly during therapy with these agents.  Atypical antipsychotic agents should be avoided in patients with a history of cardiac arrhythmias or other conditions that may increase the risk of torsade de pointes and/or sudden death, including bradycardia; hypokalemia or hypomagnesemia; and congenital long QT syndrome.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1804, 0, 'Paliperidone', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of neuroleptic agents may precipitate or aggravate a potentially fatal symptom complex known as neuroleptic malignant syndrome (NMS).  NMS is observed most frequently when high-potency agents like haloperidol are administered intramuscularly, but may occur with any neuroleptic agent given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure.  Neuroleptic agents should not be given to patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of neuroleptic agents should be carefully considered, since NMS may recur.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1805, 0, 'Paliperidone', 'Pneumonia, Aspiration', 'Esophageal dysmotility and aspiration have been associated with the use of antipsychotic drugs.  These drugs should be administered cautiously in patients at risk for aspiration pneumonia.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1806, 0, 'Paliperidone', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1807, 0, 'Paliperidone', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1808, 0, 'Paliperidone', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1809, 0, 'Paliperidone', 'Hypotension', 'The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope.  Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1810, 0, 'Paliperidone', 'Dyslipidemias', 'Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  Before or soon after initiation of antipsychotic medications, a fasting lipid profile should be obtained at baseline and monitored periodically during treatment.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1811, 0, 'Paliperidone', 'Priapism', 'Atypical antipsychotic agents with alpha-adrenergic blocking effects may cause priapism.  The condition is characterized by prolonged, often painful erections lasting longer than 4 hours.  If not treated promptly, priapism can cause irreversible damage to the erectile tissue.  Therapy with these agents should be administered cautiously in patients with a history of priapism, conditions that may predispose them to priapism (e.g., sickle cell anemia, multiple myeloma, leukemia, thalassemia), or anatomical deformations of the penis (e.g., angulation, cavernosal fibrosis, Peyronie''s disease).  Patients who experience an erection lasting longer than 4 hours, whether painful or not, should immediately discontinue the drug and seek emergency medical attention.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1812, 0, 'Paliperidone', 'Weight Gain', 'Weight gain has been observed with atypical antipsychotic use.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  When treating pediatric patients with atypical antipsychotic agents, weight gain should be monitored and assessed against that expected for normal growth.  Monitor weight at baseline and frequently thereafter.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1813, 0, 'Paliperidone', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1814, 0, 'Paliperidone', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1815, 0, 'Paliperidone', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1816, 0, 'Paliperidone', 'Intestinal Obstruction', 'An antiemetic effect was observed in preclinical studies with paliperidone.  This effect, if it occurs in humans, may mask the signs and symptoms of overdosage with certain drugs or of conditions such as intestinal obstruction, Reye''s syndrome, and brain tumor.  Cautions should be exercised when given paliperidone to these patients.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1817, 0, 'Pamidronic acid', 'Water-Electrolyte Imbalance', 'Standard hypercalcemia- related metabolic parameters, such as serum levels of calcium, phosphate, magnesium, and potassium, should be carefully monitored following initiation of therapy with pamidronate.  Cases of asymptomatic hypophosphatemia, hypokalemia, hypomagnesemia, and hypocalcemia have been reported.  Additionally, some rare cases of symptomatic hypocalcemia (including tetany), have been observed.  Patients with a history of thyroid surgery may have relative hypoparathyroidism that may predispose to hypocalcemia with pamidronate.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1818, 0, 'Pamidronic acid', 'Kidney Diseases', 'Pamidronate has been associated with renal toxicity manifested as deterioration of renal function, and potential renal failure.  Due to this risk, single doses of pamidronate disodium should not exceed 90 mg (see manufacturers instructions for appropriate infusion durations).  Patients who receive pamidronate should have serum creatinine assessed prior to each treatment.  Pamidronate is primarily eliminated intact by the kidney, and the risk of renal adverse reactions may be greater in patients with renal impairment.  Caution and regular monitoring (prior to each treatment) is recommended.', '1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1819, 0, 'Pancrelipase', 'Hyperuricemia', 'Porcine-derived pancreatic enzyme products contain purines that may increase blood uric acid levels.  Extremely high dosages of exogenous pancreatic enzymes have also been associated with hyperuricosuria and hyperuricemia.  Therapy with pancrelipase should be administered cautiously in patients with preexisting hyperuricemia, gout, or renal impairment.  Monitoring of serum uric acid levels is recommended.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1820, 0, 'Oxycodone', 'Gastrointestinal Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the gastrointestinal tract and decrease peristalsis, which can lead to elevated intraluminal pressure, spasm, and constipation following prolonged use.  In patients with severe or acute inflammatory bowel disease, the decrease in colonic motility may induce toxic megacolon.  Therapy with opioids should be administered cautiously in patients with gastrointestinal obstruction, constipation, inflammatory bowel disease, or recent gastrointestinal tract surgery.  Gastrointestinal effects appear to be the most pronounced with morphine.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1821, 0, 'Oxycodone', 'Dysentery', 'Narcotic (opioid) analgesic agents may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella, Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  These agents decrease gastrointestinal motility, which may delay the excretion of infective gastroenteric organisms and/or their toxins.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  Therapy with opioids should be avoided or administered cautiously in patients with infectious diarrhea, particularly that due to pseudomembranous enterocolitis or enterotoxin-producing bacteria or if accompanied by high fever, pus, or blood in the stool.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1822, 0, 'Oxycodone', 'Liver Diseases', 'Narcotic (opioid) analgesic agents are extensively metabolized by the liver, and several of them (e.g., codeine, hydrocodone, meperidine, methadone, morphine, propoxyphene) have active metabolites that are further converted to inactive substances.  The serum concentrations of these agents and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with liver disease.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1823, 0, 'Oxycodone', 'Premature Birth', 'The use of narcotic (opioid) analgesic agents is contraindicated in premature infants.  These agents may cross the immature blood-brain barrier to a greater extent than in adults, resulting in disproportionate respiratory depression.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1824, 0, 'Oxycodone', 'Alcoholic Intoxication', 'The use of opiate agonists is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of opiate agonists may be additive with those of alcohol.  Severe respiratory depression and death may occur.  Therapy with opiate agonists should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1825, 0, 'Oxycodone', 'Substance-Related Disorders', 'Opiate agonists have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop after prolonged use.  Abrupt cessation, reduction in dosage, or administration of an opiate antagonist such as naloxone may precipitate withdrawal symptoms.  In patients who have developed tolerance to an opiate agonist, overdosage can still produce respiratory depression and death, and cross-tolerance usually will occur with other agents in the class.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with opiate agonists.  It may be prudent to refrain from dispensing large quantities of medication to these patients.  After prolonged use or if dependency is suspected, withdrawal of opiate therapy should be undertaken gradually using a dosage-tapering schedule.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1826, 0, 'Oxycodone', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1827, 0, 'Oxycodone', 'Hypotension', 'Opiate agonists can induce vasodilation and significant hypotension, particularly when given in high dosages and/or by rapid intravenous administration.  Opiate analgesics cause vasodilatation that may exacerbate hypotension and hypoperfusion and, therefore, are contraindicated in circulatory shock.  At therapeutic analgesic dosages, ambulatory patients are more likely to experience dizziness and hypotension than patients who are confined to bed.  However, orthostatic hypotension may occur in supine patients upon rising.  Therapy with opiate agonists should be administered cautiously and initiated at reduced dosages in patients with hypovolemia, or a predisposition to hypotension.  When given by intramuscular or subcutaneous administration, clinicians should also be aware that impaired perfusion in these patients may prevent complete absorption of the drug.  With repeated injections, an excessive amount may be absorbed suddenly if normal circulation is reestablished.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1828, 0, 'Oxycodone', 'Intracranial Hypertension', 'The hypoventilation associated with administration of opiate agonists, particularly by the intravenous route, can induce cerebral hypoxia and vasodilatation with resultant increase in intracranial pressure.  Opiate agonists should not be used in patients with suspected or known head injury or increased intracranial pressure.  Also, clinicians treating such patients should be aware that opiate agonists may interfere with the evaluation of CNS function, especially with respect to consciousness levels, respiratory status, and pupillary changes.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1829, 0, 'Oxycodone', 'Respiratory Insufficiency', 'Opiate agonists may produce significant central nervous system and respiratory depression of varying duration, particularly when given in high dosages and/or by rapid intravenous administration.  Apnea may result from decreased respiratory drive as well as increased airway resistance, and rigidity of respiratory muscles may occur during rapid IV administration or when these agents are used in the induction of anesthesia.  At therapeutic analgesic dosages, the respiratory effects are usually not clinically important except in patients with preexisting pulmonary impairment.  Therapy with opiate agonists should be avoided or administered with extreme caution and initiated at reduced dosages in patients with severe CNS depression; sleep apnea; hypoxia, anoxia, or hypercapnia; upper airway obstruction; chronic pulmonary insufficiency; a limited ventilatory reserve; or other respiratory disorders.  In the presence of excessive respiratory secretions, the use of opiate agonists may also be problematic because they decrease ciliary activity and reduce the cough reflex.  Caution is also advised in patients who may be at increased risk for respiratory depression, such as comatose patients or those with head injury, intracranial lesions, or intracranial hypertension.  Clinical monitoring of pulmonary function is recommended, and equipment for resuscitation should be immediately available if parenteral or neuraxial routes are used.  Naloxone may be administered to reverse clinically significant respiratory depression, which may be prolonged depending on the opioid agent, cumulative dose, and route of administration.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1830, 0, 'Oxycodone', 'Adrenal Insufficiency', 'Patients with Addison''s disease may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  Conversely, these agents may cause or potentiate adrenal insufficiency.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with adrenocortical insufficiency.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1831, 0, 'Oxycodone', 'Gallbladder Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the biliary tract, which can lead to spasm and elevated biliary tract pressure, especially in the sphincter of Oddi.  Biliary effects appear to be the most pronounced with morphine, although they do not always occur with therapeutic doses.  Therapy with opioids should be administered cautiously in patients with biliary or gallbladder disease.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1832, 0, 'Oxycodone', 'Hypothyroidism', 'Patients with hypothyroidism may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  These agents may also exacerbate the effects of hypothyroidism such as lethargy, impaired mentation, depression, and constipation.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with uncontrolled hypothyroidism or myxedema.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1833, 0, 'Oxycodone', 'Kidney Diseases', 'Although narcotic (opioid) analgesic agents are generally metabolized by the liver, renal impairment can alter the elimination of these agents and their metabolites (some of which are pharmacologically active), resulting in drug accumulation and increased risk of toxicity.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with significantly impaired renal function.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1834, 0, 'Oxycodone', 'Epilepsy', 'Narcotic (opioid) analgesic agents may exacerbate seizures in patients with seizure disorders and, at higher dosages, have been reported to induce seizures in patients without previous history of seizures.  The proconvulsant activity may be the greatest with meperidine, the active metabolite of which is thought to be responsible.  Therapy with opioids should be administered cautiously in patients with or predisposed to seizures.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1835, 0, 'Oxycodone', 'Urinary Retention', 'Narcotic (opioid) analgesic agents may inhibit the urinary voiding reflex and increase the tone of the vesical sphincter in the bladder.  Acute urinary retention requiring catheterization may occur, particularly in patients with prostatic hypertrophy or urethral stricture and in elderly patients.  These agents may also decrease urine production via direct effects on the kidney and central stimulation of the release of vasopressin.  Therapy with opioids should be administered cautiously in patients with or predisposed to urinary retention and/or oliguria.  The effects on smooth muscle tone appear to be the most pronounced with morphine.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1836, 0, 'Oxycodone', 'Arrhythmias, Cardiac', 'Opiate agonists have cholinergic activity.  Large doses and/or rapid intravenous administration may produce bradycardia and arrhythmia via stimulation of medullary vagal nuclei.  Unlike other agents in the class, meperidine also has anticholinergic activity and may cause either bradycardia or tachycardia.  Therapy with opiate agonists should be administered cautiously in patients with a history of arrhythmias.  Clinical monitoring of cardiovascular status is recommended during therapy.  Bradycardia and other cholinergic effects produced by these agents may be controlled with atropine.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1837, 0, 'Palonosetron', 'Kidney Failure, Chronic', 'Mild to moderate renal impairment does not significantly affect palonosetron pharmacokinetic parameters.  However, total systemic exposure increased approximately 28% in patients with severe renal impairment.  Additionally, the pharmacokinetics of palonosetron have not been studied in patients with end-stage renal disease.  Caution is advised.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1838, 0, 'Palonosetron', 'Hepatic Insufficiency', 'No dosage adjustment for palonosetron is necessary for patients with mild to moderate hepatic impairment (Child-Pugh score 5 to 8).  Limited data are available in patients with severe hepatic impairment (Child-Pugh score greater than 9).  It is recommended to avoid use of palonosetron in patients with severe hepatic impairment.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1839, 0, 'Panobinostat', 'Cardiotoxicity', 'Severe and fatal cardiac ischemic events, as well as severe arrhythmias, and electrocardiogram (ECG) changes have occurred in patients receiving panobinostat.  Panobinostat may prolong cardiac ventricular repolarization (QT interval).  Do not initiate treatment with panobinostat in patients with a QTcF >450 msec or clinically significant baseline ST-segment or T-wave abnormalities.  If during treatment, the QTcF increases to >=480 msec, interrupt treatment.  Arrhythmias may be exacerbated by electrolyte abnormalities.  It is recommended to obtain ECG at baseline and periodically during treatment as clinically indicated.  Monitor patient hydration status and electrolyte blood levels, including potassium, magnesium and phosphate, at baseline and frequently as clinically indicated during therapy and correct to prevent dehydration and electrolyte disturbances.  If QT prolongation does not resolve, permanently discontinue treatment with panobinostat.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1840, 0, 'Panobinostat', 'Hepatic Insufficiency', 'Hepatic impairment can increase panobinostat exposure.  It is recommended to reduce the starting dose of panobinostat in patients with mild or moderate hepatic impairment.  Avoid the use of panobinostat in patients with severe hepatic impairment.  Liver function should be monitored prior to treatment and regularly during treatment.  If abnormal liver function tests are observed dose adjustments might be considered and the patient should be followed until values return to normal or to pretreatment levels.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1841, 0, 'Panobinostat', 'Infections', 'Localized and systemic infections, including pneumonia, bacterial infections, invasive fungal infections, and viral infections have been reported in patients taking panobinostat.  It is recommended to monitor patients for signs and symptoms of infections during treatment; if a diagnosis of infection is made, institute appropriate anti-infective treatment promptly and consider interruption or discontinuation of therapy.  Care should be exercised when prescribing this agent to patients at risk.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1842, 0, 'Panobinostat', 'Bone Marrow Failure Disorders', 'Panobinostat causes myelosuppression.  Cases of severe thrombocytopenia, neutropenia and anemia have been reported with the use of panobinostat.  It is recommended to obtain a baseline CBC and monitor the CBC frequently as clinically indicated.  Dose modifications are recommended for myelosuppression.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1843, 0, 'Panobinostat', 'Kidney Diseases', 'Mild renal impairment to severe renal impairment did not impact the plasma exposure of panobinostat.  The use of panobinostat has not been studied in patients with end stage renal disease or patients on dialysis.  Care should be exercised when using panobinostat in these patients as the dialyzability of panobinostat is unknown.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1844, 0, 'Auranofin', 'Bone Marrow Failure Disorders', 'The use of auranofin and other gold compounds is contraindicated in patients with a history of gold- induced bone marrow aplasia.  Prior to gold compounds therapy, a complete blood count with a differential, platelet count, urinalysis, and renal and liver function tests should be performed.  A complete blood count with a differential, platelet count, and urinalysis should be done at least monthly during therapy.  Hematological warning signs of gold toxicity include a drop in hemoglobin, leukopenia (WBC < 4,000/mm3), granulocytopenia (< 1,500/mm3), and thrombocytopenia (<100,000/mm3).', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1845, 0, 'Auranofin', 'Heart Failure', 'The use of gold compounds is contraindicated in patients with uncontrolled congestive heart failure.  Prior to initiation of gold compounds medical problems that might affect the signs and symptoms used to detect gold compounds toxicity should be under control.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1846, 0, 'Auranofin', 'Diabetes Mellitus', 'The use of gold compounds is contraindicated in patients with controlled diabetes mellitus.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1847, 0, 'Auranofin', 'Liver Diseases', 'The use of gold compounds is contraindicated in patients with hepatic dysfunction.  Prior to gold compounds therapy, a complete blood count with a differential, platelet count, urinalysis, and renal and liver function tests should be performed.  A complete blood count with a differential, platelet count, and urinalysis should be done at least monthly during therapy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1848, 0, 'Auranofin', 'Exanthema', 'The use of gold compounds is contraindicated in patients with urticaria or eczema.  Prior to initiation of gold therapy, medical problems that might affect the signs and symptoms used to detect gold toxicity should be under control.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1849, 0, 'Auranofin', 'Kidney Diseases', 'The use of gold compounds is contraindicated in patients with chronic renal failure.  These patients may be at increased risk for renal toxicity.  Prior to gold compounds therapy, a complete blood count with a differential, platelet count, urinalysis, and renal and liver function tests should be performed.  A complete blood count with a differential, platelet count, and urinalysis should be done at least monthly during therapy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1850, 0, 'Auranofin', 'Hypertension', 'The use of gold compounds is contraindicated in patients with severe hypertension.  Prior to initiation of gold compounds medical problems that might affect the signs and symptoms used to detect gold compounds toxicity should be under control.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1851, 0, 'Auranofin', 'Lupus Erythematosus, Systemic', 'The use of gold compounds is contraindicated in patients with systemic lupus erythematosus.  Prior to gold compounds therapy, a complete blood count with a differential, platelet count, urinalysis, and renal and liver function tests should be performed.  A complete blood count with a differential, platelet count, and urinalysis should be done at least monthly during therapy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1852, 0, 'Panitumumab', 'Water-Electrolyte Imbalance', 'The use of certain EGFR inhibitors has been associated with progressive decreases in serum magnesium levels leading to severe cases of hypomagnesemia and accompanying electrolyte abnormalities, including hypocalcemia, and hypokalemia.  The onset of hypomagnesemia and accompanying electrolyte abnormalities occurred days to months after initiation of these agents.  Periodically monitor patients for hypomagnesemia, hypocalcemia, and hypokalemia, during and for at least 8 weeks following the completion of therapy.  Caution is recommended when using these agents in patients predisposed to electrolyte imbalances and those with a history of coronary artery disease, congestive heart failure, or arrhythmias.  Replete magnesium and other electrolytes as appropriate.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1853, 0, 'Panitumumab', 'Stevens-Johnson Syndrome', 'Cutaneous reactions, in some cases severe, have been reported with the use of EGFR inhibitors.  Monitor patients who develop dermatologic or soft tissue toxicities while receiving these agents for the development of inflammatory or infectious sequelae.  It is recommended to withhold treatment, and appropriate measures should be instituted as appropriate or discontinue the use of these agents for dermatologic or soft tissue toxicity associated with severe or life-threatening inflammatory or infectious complications.  Advise patients to wear sunscreen and hats and limit sun exposure while receiving therapy with these agents as exposure to sunlight can exacerbate dermatologic toxicities.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1854, 0, 'Panitumumab', 'Eye Diseases', 'Some epidermal growth factor receptor (EGFR) inhibitors should be administered cautiously in patients with ocular disorders such as primary keratitis, ulcerative keratitis, or conjunctivitis.  It is recommended to interrupt or discontinue treatment with these agents if patients present with acute or worsening ocular disorders.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1855, 0, 'Panitumumab', 'Lung Diseases', 'The use of certain EGFR inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1856, 0, 'Panitumumab', 'Liver Failure', 'No formal pharmacokinetic studies of panitumumab have been conducted in patients with renal or hepatic impairment.  Close monitoring is recommended.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1857, 0, 'Pantoprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1858, 0, 'Pantoprazole', 'Liver Diseases', 'Pantoprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment, little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  However, data are limited concerning the pharmacokinetic disposition of pantoprazole in patients with severe hepatic impairment.  Alternate-day dosing may be appropriate in some cases.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1859, 0, 'Pantoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1860, 0, 'Pantoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1861, 0, 'Parathyroid hormone', 'Hyperparathyroidism', 'Patients known to have an underlying hypercalcemic disorder, such as primary hyperparathyroidism, should not be treated with parathyroid hormone and its analogs because of the risk of exacerbating hypercalcemia.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1862, 0, 'Parathyroid hormone', 'Neoplasms', 'Parathyroid hormone and its analogs should not be used in patients who are at increased baseline risk for osteosarcoma.  These agents should only be used if the potential benefits are considered to outweigh the potential risks.  Monitor these patients according to clinical guidelines.  Patients with bone metastases or a history of skeletal malignancies should not be treated with these agents.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1863, 0, 'Parathyroid hormone', 'Kidney Diseases', 'Parathyroid hormone is eliminated by the kidney and maximum drug levels increased with renal impairment.  No dose adjustment is recommended in patients with mild to moderate renal impairment.  No studies have been conducted in patients with severe renal impairment or in renal impairment patients on dialysis.  Care and close monitoring should be exercised when using this agent in patients with severe renal impairment or on dialysis.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1864, 0, 'Paroxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1865, 0, 'Paroxetine', 'Fractures, Bone', 'Some epidemiological studies have reported association between antidepressant treatment and bone fractures.  The extent of this risk is unknown.  Treatment with paroxetine should be administered with caution in patients with decreased bone mineral density that present unexplained bone pain, tenderness, swelling or bruising.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1866, 0, 'Paroxetine', 'Kidney Diseases', 'Paroxetine may accumulate in renal dysfunction.  The mean plasma concentration of paroxetine in patients with creatinine clearance below 30 mL/min has been shown to be approximately four times greater than that in normal patients.  Therapy with paroxetine should be administered cautiously in patients with renal impairment.  A reduction in the daily dosage is recommended if renal function is severely impaired.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1867, 0, 'Paroxetine', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1868, 0, 'Paroxetine', 'Glaucoma', 'Some SSRI antidepressants such as fluoxetine, paroxetine and sertraline may have an effect on pupil size causing dilation.  This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients.  These drugs should be used with caution in patients with angle-closure glaucoma or history of glaucoma.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1869, 0, 'Paroxetine', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1870, 0, 'Paroxetine', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1871, 0, 'Paroxetine', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1872, 0, 'Paroxetine', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1873, 0, 'Paroxetine', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1874, 0, 'Paroxetine', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1875, 0, 'Paricalcitol', 'Arrhythmias, Cardiac', 'Paricalcitol, a vitamin D analog, reduces hyperparathyroidism associated with chronic renal failure without significant increase in serum calcium levels.  Serum calcium and phosphate concentrations can increase during therapy with paricalcitol and may exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended. .', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1876, 0, 'Paricalcitol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1877, 0, 'Paricalcitol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1878, 0, 'Paricalcitol', 'Liver Diseases', 'Paricalcitol is metabolized by the liver. Parent compound and metabolites are primarily eliminated by in the bile and feces.  Paricalcitol metabolites have not been characterized or identified. Metabolic and therapeutic activity of paricalcitol may be altered in patients with hepatic impairment.  Therapy with paricalcitol should be administered cautiously in patients with hepatobiliary dysfunction.  Clinical monitoring of hepatobiliary function, parathyroid hormone and calcium levels is recommended.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1879, 0, 'Paromomycin', 'Intestinal Obstruction', 'The use of oral aminoglycosides is contraindicated in patients with intestinal obstruction.  Orally administered aminoglycosides are poorly absorbed from the gastrointestinal tract and primarily eliminated unchanged in the feces.  Drug retention and enhanced systemic absorption may occur in the presence of intestinal obstruction, increasing the risk of oto- and nephrotoxicity associated with these drugs.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1880, 0, 'Paromomycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1881, 0, 'Paromomycin', 'Gastroenteritis', 'Like other aminoglycosides, paromomycin is potentially oto- and nephrotoxic.  While it is poorly absorbed from the gastrointestinal tract, significant systemic absorption may occur if intestinal mucosal integrity is compromised.  Therapy with paromomycin should be administered cautiously in patients with inflammatory or ulcerative gastrointestinal diseases because of the potential for enhanced absorption of the drug.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1882, 0, 'Pasireotide', 'Hepatic Insufficiency', 'The use of pasireotide causes elevations in ALT or AST.  No dose adjustment is required in patients with mild hepatic impairment, but is required for patients with moderate hepatic impairment.  The use of pasireotide should be avoided in patients with severe hepatic impairment.  Regular monitoring of liver function test is recommended and interruption of treatment should be considered if abnormal values exceeding 5 times ULN or rising values are obtained during the course of therapy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1883, 0, 'Pasireotide', 'Long QT Syndrome', 'The use of pasireotide is associated with QT prolongation.  Pasireotide should be used with caution in patients who are at significant risk of developing QT prolongation.  It is recommended to correct levels of hypokalemia and hypomagnesemia prior to starting therapy with this agent.  Assess ECG at the beginning of therapy and monitor during therapy.  Care should be taken in predisposed patients.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1884, 0, 'Pasireotide', 'Adrenal Insufficiency', 'Treatment with somatostatin analogs may suppress the pituitary hormones other than GH/IGF-1.  It is recommended to monitor pituitary function prior to initiation of therapy and periodically during treatment, as clinically appropriate.  Patients should be monitored for and instructed on the signs and symptoms of adrenal insufficiency during therapy.  If adrenal insufficiency is suspected it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1885, 0, 'Pasireotide', 'Bradycardia', 'Bradycardia has been reported with the use of somatostatin analogs.  It is recommended to carefully monitor patients with cardiac disorders for the development of bradycardia.  Dose adjustments of beta-blockers, calcium channel blockers, or correction of electrolyte disturbances may be necessary.  Care should be taken when initiating treatment with these agents in patients with bradycardia.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1886, 0, 'Pasireotide', 'Cholelithiasis', 'Somatostatin analogs may reduce gallbladder motility and lead to gallstones formation.  It is recommended to assess the gallbladder prior to starting therapy and periodically thereafter.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1887, 0, 'Pasireotide', 'Diabetes Mellitus', 'Elevations in blood glucose levels have been reported with the use of somatostatin analogs.  Cushing''s disease patients with poor glycemic control may be at a higher risk of developing severe hyperglycemia and associated complications, e.g., ketoacidosis.  It is recommended to assess the glycemic status of hemoglobin A1C prior to starting treatment with these agents.  Self-monitoring of blood glucose and/or FPG assessments should be done every week for the first two to three months and periodically thereafter, as clinically appropriate, as well as over the first two to four weeks after any dose increase.  If uncontrolled hyperglycemia persists, despite appropriate medical management, the dose of these agents should be reduced or discontinued.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1888, 0, 'Pegfilgrastim', 'Glomerulonephritis', 'Although it has been reported that renal dysfunction has no effect on the pharmacokinetics of colony stimulating factors (CSF), filgrastim and pegfilgrastim may cause glomerulonephritis.  Symptoms include swelling of the face or ankles, dark colored urine, or blood in the urine, or a decrease in urine production.  Advise patients to report signs or symptoms of glomerulonephritis immediately.  Monitoring of patients with renal dysfunction is recommended.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1889, 0, 'Pegfilgrastim', 'Leukemia, Myeloid', 'Colony stimulating factors primarily stimulates the proliferation of neutrophils but may also, theoretically, enhance tumor growth, particularly in myeloid malignancies.  Therapy with these drugs should be administered cautiously in patients with myeloid tumors.  Additionally, if used for PBPC (peripheral blood progenitor cell) collection in such patients, tumor cells may be released from the marrow and collected in the leukapheresis product.  The effect of reinfusion of tumor cells is uncertain at this time.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1890, 0, 'Pegfilgrastim', 'Leukocytosis', 'Filgrastim and pegfilgrastim are growth factors for neutrophil progenitor cells.  Therefore, these should not be used in patients with leukocytosis.  If excessive white blood cell counts occur during CSF therapy, treatment should be interrupted or the dosage reduced.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1891, 0, 'Pegaptanib (ophthalmic)', 'Eye Infections', 'Drugs requiring intravitreal administration (including aflibercept, faricimab, pegaptanib, and ranibizumab) are contraindicated in patients with active intraocular inflammation or ocular/periocular infections; intravitreal injections have been associated with endophthalmitis.  Patients should be advised to seek immediate medical attention from an ophthalmologist if the eye becomes red, photosensitive, or painful, or if a change in vision occurs in the days following drug administration.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1892, 0, 'Pegaspargase', 'Hemorrhagic Disorders', 'The use of pegaspargase is contraindicated in patients who developed significant bleeding with previous L-asparaginase therapy.  Pegaspargase interferes with coagulation factors, and both thrombosis and hemorrhage have been observed.  Therapy with pegaspargase should be administered with extreme caution to patients with or predisposed to coagulopathies.  Patients should be instructed to immediately report any signs or symptoms of thrombosis or bleeding.  Close clinical monitoring of hematopoetic function and coagulation profiles is recommended.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1893, 0, 'Pegaspargase', 'Pancreatitis', 'The use of pegaspargase is contraindicated in patients with or a history of pancreatitis.  Pegaspargase can cause decreased insulin synthesis or inflammation and/or necrosis of cells of the pancreas.  Fulminant and fatal pancreatitis has occurred.  Clinical monitoring of pancreatic function, including serum amylase levels, is recommended.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1894, 0, 'Pegaspargase', 'Liver Diseases', 'Reversible liver abnormalities such as elevated liver transaminase and bilirubin levels and decreased albumin synthesis have been reported during pegaspargase therapy.  Fatty changes and liver failure have occurred.  Patients should be instructed to immediately report any sign or symptoms of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Therapy with pegaspargase should be administered cautiously to patients with or predisposed to compromised hepatic function.  Clinical monitoring of hepatic function is recommended.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1895, 0, 'Pegaspargase', 'Hyperglycemia', 'Hyperglycemia requiring insulin therapy has been reported during pegaspargase therapy.  Therapy with pegaspargase should be administered cautiously to patients with diabetes mellitus.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1896, 0, 'Patiromer', 'Gastrointestinal Diseases', 'The use of patiromer should be avoided in patients with severe constipation, bowel obstruction or impaction, including abnormal post-operative bowel motility disorders, as this agent may be ineffective and may worsen gastrointestinal conditions.  Therapy with patiromer should be administered cautiously in patients with a history of bowel obstruction or major gastrointestinal surgery, severe gastrointestinal disorders, or swallowing disorders.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1897, 0, 'Patiromer', 'Hypomagnesemia 1, Intestinal', 'Patiromer binds to magnesium in the colon, which can lead to hypomagnesemia.  It is recommended to monitor serum magnesium concentrations during therapy.  Therapy with patiromer should be administered cautiously in patients with or predisposed to magnesium deficiency.  Consider magnesium supplementation in patients who develop low serum magnesium levels.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1898, 0, 'Pegvisomant', 'Diabetes Mellitus', 'Pegvisomant is an analog of human growth hormone (GH) that selectively binds to growth hormone (GH) receptors on cell surfaces, where it blocks the binding of endogenous GH, and thus interferes with GH signal transduction.  The use of growth hormones opposes the effects of insulin on carbohydrate metabolism by decreasing insulin sensitivity; therefore, glucose intolerance may improve in some patients treated with pegvisomant.  Diabetic patients should be monitored closely, and the doses of anti-diabetic drugs may be reduced as necessary to avoid hypoglycemia.  Blood glucose levels should be evaluated as appropriate.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1899, 0, 'Pegvisomant', 'Liver Diseases', 'Asymptomatic, transient elevations in transaminases up to 15 times ULN have been observed in patients treated with pegvisomant.  Baseline serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum total bilirubin (TBIL), and alkaline phosphatase (ALP) levels should be obtained prior to initiating therapy with pegvisomant.  Care should be exercised when using this agent in patients with liver dysfunction and its use should be used in accordance with the information presented in the manufacturer prescribing information with respect to liver test abnormalities.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1900, 0, 'Pegademase', 'Blood Platelet Disorders', 'Pegademase bovine should be used with caution in patients with thrombocytopenia.  This agent should not be used in patients with severe thrombocytopenia.  Pegademase is administered by IM injection and the risk of bleeding is increased in the presence of severe thrombocytopenia.  Therapy with pegademase bovine should be administered cautiously in patients with coagulation or platelet function disorders.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1901, 0, 'Acetaminophen', 'Alcoholism', 'Chronic alcohol abusers may be at increased risk of hepatotoxicity during treatment with acetaminophen (APAP).  Severe liver injury, including cases of acute liver failure resulting in liver transplant and death, has been reported in patients using acetaminophen.  Therapy with acetaminophen should be administered cautiously, if at all, in patients who consume three or more alcoholic drinks a day.  In general, patients should avoid drinking alcohol while taking acetaminophen-containing medications.  Patients should be warned not to exceed the maximum recommended total daily dosage of acetaminophen (4 g/day in adults and children 12 years of age or older), and to read all prescription and over-the-counter medication labels to ensure they are not taking multiple acetaminophen-containing products, or check with a healthcare professional if they are unsure.  They should also be advised to seek medical attention if they experience signs and symptoms of liver injury such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, and jaundice.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1902, 0, 'Acetaminophen', 'Liver Diseases', 'Acetaminophen is primarily metabolized in the liver to inactive forms.  However, small quantities are converted by minor pathways to metabolites that can cause hepatotoxicity or methemoglobinemia.  Patients with hepatic impairment may be at increased risk of toxicity due to increased minor metabolic pathway activity.  Likewise, chronic or overuse of acetaminophen can saturate the primary hepatic enzymes and lead to increased metabolism by minor pathways.  Severe liver injury, including cases of acute liver failure resulting in liver transplant and death, has been reported in patients using acetaminophen.  Therapy with acetaminophen should be administered cautiously in patients with hepatic insufficiency.  Clinical monitoring of hepatic function is recommended.  Instruct patients to avoid drinking alcohol while taking acetaminophen-containing medications.  Patients should be warned not to exceed the maximum recommended total daily dosage of acetaminophen (4 g/day in adults and children 12 years of age or older), and to read all prescription and over-the-counter medication labels to ensure they are not taking multiple acetaminophen-containing products, or check with a healthcare professional if they are unsure.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1903, 0, 'Acetaminophen', 'Phenylketonurias', 'Several oral acetaminophen and acetaminophen-combination products, particularly flavored chewable tablets, contain the artificial sweetener, aspartame (NutraSweet).  Aspartame is converted to phenylalanine in the gastrointestinal tract following ingestion.  Chewable and effervescent formulations of acetaminophen products may also contain phenylalanine.  The aspartame/phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e. phenylketonurics).', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1904, 0, 'Avanafil', 'Cardiovascular Diseases', 'The use of phosphodiesterase-5 (PDE5) inhibitors is not recommended in patients with preexisting cardiovascular disease for whom sexual activity is inadvisable due to the potential cardiac risk.  Physicians should also consider the vasodilatory effect of these drugs and whether they may adversely affect patients with underlying cardio- and/or cerebrovascular conditions, in particular those who have suffered a myocardial infarction, stroke, or life-threatening arrhythmia within the last 6 months; those with resting hypotension (BP < 90/50) or hypertension (BP > 170/110); and those with unstable angina associated with cardiac failure or coronary artery disease.  There are no controlled clinical data on the safety or efficacy in such patients.  Other adverse cardiovascular effects reported include angina pectoris, myocardial infarction, AV block, ventricular arrhythmia, tachycardia, palpitation, hypotension, postural hypotension, syncope, cerebral thrombosis, cerebrovascular hemorrhage, transient ischemic attack, cardiac arrest, heart failure, and hypertension.  Many of these events occurred in patients with cardiovascular risk factors and during or shortly after sexual activity.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1905, 0, 'Avanafil', 'Kidney Diseases', 'The plasma clearance of phosphodiesterase-5 (PDE5) inhibitors may be decreased in patients with severe renal impairment, resulting in drug accumulation.  Therapy with these agents should be avoided in patients with severe renal disease or on renal dialysis.  Dose adjustments might be needed based on individual renal assessment and tolerability if used in these patients.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1906, 0, 'Avanafil', 'Priapism', 'Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours) have been reported during treatment with phosphodiesterase-5 (PDE 5) inhibitors.  Priapism may result in penile tissue damage and permanent loss of potency if not treated promptly.  These agents should be used cautiously in patients with conditions that may predispose them to priapism such as sickle cell anemia, multiple myeloma, or leukemia, and those with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie''s disease).  If an erection persists longer than 4 hours, the patient should seek immediate medical assistance.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1907, 0, 'Avanafil', 'Alcoholism', 'Alcohol consumption may intensify the pressure-lowering effects of mild vasodilators, such as phosphodiesterase 5 (PDE5) inhibitors.  Therefore, patients that consume alcohol should be warned to limit alcohol intake while receiving these agents.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1908, 0, 'Avanafil', 'Hearing Loss', 'Use of phosphodiesterase-5 (PDE5) inhibitors has been associated with sudden decrease or loss of hearing, which may be accompanied by tinnitus or dizziness.  Patients with hearing problems should stop taking these agents and seek prompt medical care.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1909, 0, 'Avanafil', 'Liver Diseases', 'Phosphodiesterase 5 (PDE-5) inhibitors are cleared predominantly by hepatic metabolism.  The pharmacokinetic disposition of these agents has not been assessed in patients with severe hepatic impairment.  No dosage modification is recommended for patients with mild to moderate hepatic impairment, however, therapy with these agents should not be administered to patients with severe hepatic impairment.  In patients with mild hepatic impairment a lower dose of these agents should be used as initial therapy.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1910, 0, 'Avanafil', 'Retinitis Pigmentosa', 'Phosphodiesterase-5 (PDE5) inhibitors have been associated with transient impairment of color discrimination (blue/green) and blue- or color-tinged vision.  These agents also inhibit phosphodiesterase-6 (PDE6), to a much lesser extent, which is involved in phototransduction in the retina.  There are no controlled clinical data on the safety in patients with retinitis pigmentosa, a minority of whom may have genetic disorders of retinal phosphodiesterases.  Therapy with these agents should be avoided in such patients.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1911, 0, 'Avanafil', 'Epilepsy', 'The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures.  Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1912, 0, 'Peginterferon alfa-2b', 'Kidney Diseases', 'Proteinuria (rare), not associated with a decrease in serum protein, is the most common renal toxicity observed with interferon- alfa therapy.  Increased BUN and serum creatinine levels, hematuria, acute renal failure and nephrotic syndrome have also been reported.  Therapy with interferon alfa should be administered cautiously to patients with severe renal dysfunction.  Renal function should be evaluated in all patients before initiation of interferon- alfa therapy.  In addition, patients with any degree of renal impairment should be carefully monitored for laboratory abnormalities and decreased creatinine clearance.  A reduced dose of medication is recommended in patients with low CrCl (less than 50 mL/min - 30 mL/min).', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1913, 0, 'Peginterferon alfa-2b', 'Autoimmune Diseases', 'Antiviral interferons may exacerbate autoimmune disorders such as myositis, thyroiditis, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, or autoimmune hepatitis.  Therapy should be avoided or administered with extreme caution in patients with autoimmune disorders.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1914, 0, 'Peginterferon alfa-2b', 'Heart Diseases', 'Hypertension, arrhythmias, angina, myocardial infarction, cardiomyopathy, and congestive heart failure have been reported during interferon therapy.  Therapy with interferons should be administered with caution in patients with compromised cardiac function.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1915, 0, 'Peginterferon alfa-2b', 'Central Nervous System Diseases', 'Reversible CNS effects such as seizures, mental status changes, manic behavior or psychotic reactions, gait disturbances, and dizziness have occurred in patients receiving interferons.  Therapy with interferons should be administered cautiously in patients with or predisposed to seizures, psychiatric disorders, or conditions affecting posture or gait.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1916, 0, 'Peginterferon alfa-2b', 'Depressive Disorder', 'Interferons (alfa or beta) can induce depression and suicidal behavior.  Suicidal attempts and suicides have been reported.  Therapy with interferons (alfa or beta) should be administered cautiously to patients with or predisposed to mental depression.  Clinical monitoring of psychological status is recommended.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1917, 0, 'Peginterferon alfa-2b', 'Hypothyroidism', 'Thyroid abnormalities, hypothyroidism or hyperthyroidism, have been reported in patients administered interferons.  Therapy with interferons should be administered cautiously to patients with thyroid dysfunction.  If thyroid control cannot be maintained within normal limits with medication, interferon-alfa should be discontinued.  Clinical monitoring of thyroid function is recommended.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1918, 0, 'Peginterferon alfa-2b', 'Hepatitis, Autoimmune', 'The use of peginterferons alfa are contraindicated in patients with autoimmune hepatitis.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1919, 0, 'Peginterferon alfa-2b', 'Liver Failure', 'The use of peginterferons alfa are contraindicated in patients with hepatic decompensation (Child-Pugh score greater than 6, class B or C) in cirrhotic patients before treatment, and in patients with hepatic decompensation (Child-Pugh score greater or equal to 6) that have chronic hepatitis C coinfected with HIV.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1920, 0, 'Peginterferon alfa-2b', 'Hemoglobinopathies', 'The use of peginterferon alfa-2b is contraindicated in patients with hemoglobinopathies such as, thalassemia major, and sickle-cell anemia.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1921, 0, 'Peginterferon alfa-2b', 'Colitis', 'Fatal and nonfatal ulcerative or hemorrhagic/ischemic colitis have been observed within 12 weeks of the start of alpha interferon treatment.  Abdominal pain, bloody diarrhea, and fever are the typical manifestations.  Treatment should be discontinued immediately in patients who develop these signs and symptoms.  The colitis usually resolves within 1 to 3 weeks of discontinuation of alpha interferons.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1922, 0, 'Peginterferon alfa-2b', 'Diabetes Mellitus', 'Flu-like symptoms frequently associated with interferon-alfa therapy can precipitate ketoacidosis in diabetic patients.  Therapy with interferon alfa should be administered cautiously in patients with diabetes mellitus.  Clinical monitoring of blood glucose concentrations and anti-diabetic therapy is recommended.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1923, 0, 'Peginterferon alfa-2b', 'Bone Marrow Failure Disorders', 'Interferons (alfa and gamma) induce a dose-dependent, generally mild, myelosuppression.  Leukopenia is the primary manifestation.  Thrombocytopenia and anemia occur less frequently.  Therapy with interferons (alfa and gamma) should be administered cautiously to patients with bone marrow suppression.  Clinical monitoring of hematopoietic function is recommended.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1924, 0, 'Peginterferon alfa-2b', 'Peripheral Nervous System Diseases', 'Paresthesia and numbness have been reported during interferon therapy.  Therapy with interferons should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1925, 0, 'Peginterferon alfa-2b', 'Endocrine System Diseases', 'Peginterferons alfa can cause or aggravate hypothyroidism, hyperthyroidism, hyperglycemia, hypoglycemia and diabetes mellitus.  Treatment should be administered with caution on patients with these conditions.  Treatment should not be initiated if the condition cannot be effectively treated by medication.  Therapy should be discontinued if any of these conditions develops during treatment and it cannot be controlled with medication.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1926, 0, 'Peginterferon alfa-2b', 'Eye Diseases', 'Decrease or loss of vision, retinopathy including macular edema, retinal artery or vein thrombosis, retinal hemorrhages and cotton wool spots, optic neuritis, papilledema, and serious retinal detachment can be induced or aggravated by alpha interferons.  All patients should receive an eye examination at baseline and caution should be exercised in patients with preexisting ophthalmologic disorders.  Patients should have periodic ophthalmologic exams during treatment.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1927, 0, 'Peginterferon alfa-2b', 'Pancreatitis', 'Fatal and nonfatal pancreatitis has been observed in patients treated with alpha interferon.  Therapy should be suspended in patients with signs and symptoms suggestive of pancreatitis and discontinued in patients diagnosed with pancreatitis.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1928, 0, 'Peginterferon alfa-2b', 'Respiration Disorders', 'Dyspnea, pulmonary infiltrates, pneumonia, bronchiolitis, pulmonary hypertension, and other pulmonary disorders resulting in respiratory failure and/or death may be induced or aggravated by alpha interferon therapy.  Caution should be used when used in patients with preexisting pulmonary disorders.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1929, 0, 'Pembrolizumab', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1930, 0, 'Pembrolizumab', 'Cardiovascular Diseases', 'The use of monoclonal antibodies administered via IV infusion may cause serious infusion reactions, including bronchospasm, hypoxia, dyspnea, fluctuations in blood pressure, laryngeal edema and pulmonary edema.  Caution should be taken in patients with a history of cardiopulmonary disease as they may require additional post-infusion medications to manage respiratory complications.  It is recommended to administer required intravenous hydration and premedication with antihistamines, analgesics, and antipyretics before administration.  Monitor closely for signs and symptoms of infusion reactions during and for at least 4 hours following completion of each infusion in a setting where cardiopulmonary resuscitation medication and equipment are available.  Immediately interrupt or permanently discontinue treatment and institute supportive management for severe or prolonged infusion reactions as appropriate.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1931, 0, 'Pembrolizumab', 'Tumor Lysis Syndrome', 'Tumor lysis syndrome (TLS) has occurred in patients receiving certain monoclonal antibodies.  Patients with high tumor burden and those with high circulating lymphocyte counts of greater than 25 X 10^9/L have a higher risk of developing TLS.  Consider tumor lysis prophylaxis prior to the infusion with anti-hyperuricemics and hydration beginning 12 to 24 hours prior to infusion.  It is recommended to correct electrolytes abnormalities, and monitor renal function in patients who develop TLS.  Monitor for signs and symptoms of TLS and temporary interruption or discontinuation of therapy might be required.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1932, 0, 'Pembrolizumab', 'Myasthenia Gravis', 'Certain PD-1 inhibitors such as nivolumab and pembrolizumab should be used with caution in patients with myasthenia gravis (MG).  Worsening of myasthenic weakness has been reported in people with previously diagnosed MG.  It is recommended to advise patients with MG and cancer considering cancer immunotherapy about this possible side effect.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1933, 0, 'Pembrolizumab', 'Colitis', 'Immune-mediated colitis has been reported with the use of pembrolizumab.  Monitor patients for signs and symptoms of colitis.  It is recommended to administer corticosteroids at a dose of 1 to 2 mg/kg/day prednisone equivalents followed by corticosteroid taper for moderate to severe or life-threatening colitis.  Withhold treatment for moderate or severe colitis, and permanently discontinue therapy for life-threatening colitis.  If appropriate modify the dose according to manufacturer recommendations.  Care should be taken when using pembrolizumab in patients with inflammatory bowel disease.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1934, 0, 'Pembrolizumab', 'Diabetes Mellitus', 'Pembrolizumab can cause type 1 diabetes mellitus, including diabetic ketoacidosis.  Monitor for hyperglycemia or other signs and symptoms of diabetes.  Administer insulin for type 1 diabetes, and withhold pembrolizumab and administer anti-hyperglycemics in patients with severe hyperglycemia.  Care should be exercised when using pembrolizumab in diabetic patients.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1935, 0, 'Pembrolizumab', 'Hepatic Insufficiency', 'Pembrolizumab can cause immune-mediated hepatitis.  Based on a population pharmacokinetic analysis, no dose adjustment is recommended for patients with mild hepatic impairment.  Caution is recommended when using pembrolizumab in patients with moderate or severe hepatic impairment as there is insufficient information to determine whether there are clinically important differences in the CL of pembrolizumab in these patients.  Monitor patients for abnormal liver tests prior to and periodically during treatment.  It is recommended to administer corticosteroids at a dose of 0.5 to 1 mg/kg/day prednisone equivalents for grade 2 hepatitis and 1 to 2 mg/kg/day prednisone equivalents for grade 3 or greater hepatitis followed by corticosteroid taper and, based on severity of liver enzyme elevations, withhold or discontinue treatment.  If appropriate modify the dose according to manufacturer recommendations.  Care should be taken when using pembrolizumab in patients with hepatic impairment.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1936, 0, 'Pembrolizumab', 'Multiple Myeloma', 'The use of pembrolizumab is not recommended in patients with multiple myeloma with a PD-1 or PD-L1 blocking antibody in combination with a thalidomide analog plus dexamethasone.  In two randomized clinical trials in patients with multiple myeloma, the addition of pembrolizumab to a thalidomide analog plus dexamethasone, a use for which no PD-1 or PD-L1 blocking antibody is indicated, resulted in increased mortality.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1937, 0, 'Pembrolizumab', 'Pneumonia', 'Immune-mediated pneumonitis, including fatal cases have been reported with the use of pembrolizumab.  Monitor patients for signs with radiographic imaging and for symptoms of pneumonitis.  It is recommended to administer corticosteroids at a dose of 1 to 2 mg/kg/day prednisone equivalents for moderate or more severe pneumonitis, followed by corticosteroid taper.  Permanently discontinue therapy for severe, life-threatening or recurrent moderate pneumonitis and withhold therapy until resolution for moderate pneumonitis.  If appropriate modify the dose according to manufacturer recommendations.  Care should be taken when using pembrolizumab in patients with pulmonary infections.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1938, 0, 'Pembrolizumab', 'Kidney Diseases', 'Pembrolizumab can cause immune-mediated nephritis.  Monitor patients for changes in renal function, including elevated serum creatinine, prior to and periodically during treatment.  It is recommended to administer corticosteroids at a dose of 1 to 2 mg/kg/day prednisone equivalents followed by corticosteroid taper for moderate or greater nephritis.  Withhold pembrolizumab for moderate and permanently discontinue treatment for severe or life-threatening nephritis.  Care should be taken when using pembrolizumab in patients with renal dysfunction.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1939, 0, 'Pembrolizumab', 'Thyroid Diseases', 'Pembrolizumab can cause autoimmune thyroid disorders.  Monitor thyroid function prior to, periodically during treatment, and as indicated based on clinical evaluation.  Administer hormone-replacement therapy for hypothyroidism.  Initiate medical management for control of hyperthyroidism.  Withhold or discontinue pembrolizumab for severe or life-threatening hyperthyroidism.  Care should be take when using this agent in patients with thyroid disease.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1940, 0, 'Pegloticase', 'Glucosephosphate Dehydrogenase Deficiency', 'The antihyperuricemic agents pegloticase and rasburicase are contraindicated in patients deficient in glucose-6-phosphate-dehydrogenase (G6PD), as these have shown to cause severe hemolytic reactions and methemoglobinemia.  Patients at high risk of G6PD deficiency such as patients of African, Mediterranean or Southern Asian ancestry, should be screened prior to starting treatment.  Treatment with any of these drugs should be discontinued immediately and permanently in any patient developing hemolysis or methemoglobinemia.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1941, 0, 'Pegloticase', 'Heart Failure', 'Pegloticase has not been formally studied in patients with congestive heart failure, and some patients in clinical trials have experienced exacerbation.  Caution should be exercised when using pegloticase in these patients and close monitoring following the infusion is recommended.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1942, 0, 'Pemoline', 'Mental Disorders', 'The use of central nervous system (CNS) stimulants is contraindicated in patients with marked agitation and/or anxiety, since these symptoms may be aggravated.  CNS stimulants may also exacerbate symptoms of behavior disturbance and thought disorder in psychotic patients, particularly children.  Therapy with CNS stimulants should be administered cautiously in patients with a history of psychosis or a predisposition to agitated states.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1943, 0, 'Pemoline', 'Heart Diseases', 'The use of CNS stimulants is contraindicated in patients with significant cardiovascular impairment such as uncompensated heart failure, severe coronary disease, severe hypertension (including that associated with hyperthyroidism or pheochromocytoma), cardiac structural abnormalities, serious arrhythmias, etc.  Sudden death has been reported in adults and children taking CNS stimulant treatment.  Additionally, stroke, myocardial infarction, chest pain, syncope, arrhythmias and other symptoms have been reported in adults under treatment.  A careful assessment of the cardiovascular status should be done in patients being considered for treatment.  This includes family history, physical exam and further cardiac evaluation (EKG and echocardiogram).  Patients who develop symptoms should have a detailed cardiac evaluation and if needed, treatment should be suspended.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1944, 0, 'Pemoline', 'Hypertension', 'CNS stimulant medications have shown to increase blood pressure, and their use might be contraindicated in patients with severe hypertension.  Caution should be used when administering to patients with preexisting high blood pressure and other cardiovascular conditions.  All patients under treatment should be regularly monitored for changes in blood pressure and heart rate.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1945, 0, 'Pemoline', 'Liver Diseases', 'In general, CNS stimulants are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with CNS stimulants should be administered cautiously in patients with moderate to severe liver disease, and the dosage should be adjusted accordingly.  Additionally, postmarketing reports have shown that atomoxetine can cause severe liver injury.  Laboratory testing should be done at the first sign or symptom of liver dysfunction (jaundice, dark urine, upper quadrant tenderness) and treatment should be discontinued in patients with evidence of liver injury.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1946, 0, 'Pemoline', 'Substance-Related Disorders', 'Central nervous system (CNS) stimulants, especially amphetamines, have significant potential for habituation and abuse.  Tolerance, psychological dependence and severe social dysfunction can develop after prolonged use.  Frank psychotic episodes may also occur in association with chronic intoxication.  Therapy with CNS stimulants should be administered cautiously, if at all, in patients with a history of alcohol or substance abuse.  The use of amphetamines is considered by manufacturers to be contraindicated in such patients.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1947, 0, 'Pemoline', 'Tics', 'Central nervous system (CNS) stimulants have been reported to exacerbate Tourette''s syndrome and other motor and phonic tics.  Therapy with CNS stimulants, if necessary, should be administered cautiously in patients with tic disorders or family history of Tourette''s syndrome.  The manufacturers of the CNS stimulants, methylphenidate (racemic) and dexmethylphenidate (the more pharmacologically active d-enantiomer), consider their use to be contraindicated in such patients.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1948, 0, 'Pemoline', 'Kidney Diseases', 'Pemoline is primarily eliminated by the kidney.  The plasma clearance of pemoline may be decreased and the half-life prolonged in patients with renal impairment.  Therapy with pemoline should be administered cautiously in patients with significantly impaired renal function.  Dosage adjustments may be necessary.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1949, 0, 'Pemoline', 'Bipolar Disorder', 'Central nervous system (CNS) stimulants may induce a mixed/manic episode in patients with bipolar disorder.  Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression).  Close monitoring is recommended when using these agents in patients with bipolar disorders.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1950, 0, 'Pemoline', 'Psychotic Disorders', 'Central nervous system (CNS) stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder.  Close monitoring is recommended when using these agents in patients with psychotic disorders.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1951, 0, 'Pemoline', 'Epilepsy', 'Due to general central nervous system stimulation, therapy with CNS stimulant drugs may cause seizures.  These drugs may lower the convulsive threshold in patients with prior history of seizures or EEG abnormalities, and very rarely in patients with no previous history of seizures.  Therapy with CNS stimulants should be used with caution in patients with or predisposed to seizures.  If seizures appear, therapy should be discontinued.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1952, 0, 'Penbutolol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1953, 0, 'Penbutolol', 'Shock, Cardiogenic', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with hypotension or cardiogenic shock.  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to further depress cardiac output and blood pressure, which can be detrimental in these patients.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1954, 0, 'Penbutolol', 'Heart Failure', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) in general should not be used in patients with overt congestive heart failure (CHF).  Sympathetic stimulation may be important in maintaining the hemodynamic function in these patients, thus beta-blockade can worsen the heart failure.  However, therapy with beta-blockers may be beneficial and can be administered cautiously in some CHF patients provided they are well compensated and receiving digitalis, diuretics, an ACE inhibitor, and/or nitrates.  Carvedilol, specifically, is indicated for use with these agents in the treatment of mild to severe heart failure of ischemic or cardiomyopathic origin.  There is also increasing evidence that the addition of a beta-blocker to standard therapy can improve morbidity and mortality in patients with advanced heart failure, although it is uncertain whether effectiveness varies significantly with the different agents.  Data from one meta-analysis study suggest a greater reduction of mortality risk for nonselective beta-blockers than for beta-1 selective agents.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1955, 0, 'Penbutolol', 'Diabetes Mellitus', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask symptoms of hypoglycemia such as tremors, tachycardia and blood pressure changes.  In addition, the nonselective beta-blockers (e.g., propranolol, pindolol, timolol) may inhibit catecholamine-mediated glycogenolysis, thereby potentiating insulin-induced hypoglycemia and delaying the recovery of normal blood glucose levels.  Since cardioselectivity is not absolute, larger doses of beta-1 selective agents may demonstrate these effects as well.  Therapy with beta-blockers should be administered cautiously in patients with diabetes or predisposed to spontaneous hypoglycemia.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1956, 0, 'Penbutolol', 'Diseases requiring hemodialysis', 'Therapy with beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in patients requiring hemodialysis.  When given after dialysis, hemodynamic stability should be established prior to drug administration to avoid marked falls in blood pressure.  The hemodynamic status should be closely monitored before and after the dose.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1957, 0, 'Penbutolol', 'Hypersensitivity', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) in patients with a history of allergic reactions or anaphylaxis may be associated with heightened reactivity to culprit allergens.  The frequency and/or severity of attacks may be increased during beta-blocker therapy.  In addition, these patients may be refractory to the usual doses of epinephrine used to treat acute hypersensitivity reactions and may require a beta-agonist such as isoproterenol.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1958, 0, 'Penbutolol', 'Myocardial Ischemia', 'Heightened sensitivity to catecholamines may occur after prolonged use of beta-adrenergic receptor blocking agents (aka beta-blockers).  Exacerbation of angina, myocardial infarction and ventricular arrhythmias have been reported in patients with coronary artery disease following abrupt withdrawal of therapy.  Cessation of beta-blocker therapy, whenever necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks in patients with coronary insufficiency.  Patients should be advised not to discontinue treatment without first consulting with the physician.  In patients who experience an exacerbation of angina following discontinuation of beta-blocker therapy, the medication should generally be reinstituted, at least temporarily, along with other clinically appropriate measures.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1959, 0, 'Penbutolol', 'Peripheral Vascular Diseases', 'Due to their negative inotropic and chronotropic effects on the heart, beta-adrenergic receptor blocking agents (aka beta-blockers) reduce cardiac output and may precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.  In addition, the nonselective beta-blockers (e.g., propranolol, pindolol, timolol) may attenuate catecholamine-mediated vasodilation during exercise by blocking beta-2 receptors in peripheral vessels.  Therapy with beta-blockers should be administered cautiously in patients with peripheral vascular disease.  Close monitoring for progression of arterial obstruction is advised.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1960, 0, 'Penbutolol', 'Asthma', 'Some beta-adrenergic receptor blocking agents (i.e., non-cardioselective beta-blockers) are contraindicated in patients with bronchial asthma or with a history of bronchial asthma, or severe chronic obstructive pulmonary disease.  In general, beta-adrenergic receptor blocking agents should not be used in patients with bronchospastic diseases.  Beta blockade may adversely affect pulmonary function by counteracting the bronchodilation produced by catecholamine stimulation of beta-2 receptors.  If beta-blocker therapy is necessary in these patients, an agent with beta-1 selectivity (e.g., atenolol, metoprolol, betaxolol) is considered safer, but should be used with caution nonetheless.  Cardioselectivity is not absolute and can be lost with larger doses.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1961, 0, 'Penbutolol', 'Liver Diseases', 'Penbutolol is primarily metabolized by the liver.  Patients with liver disease may be at greater risk for adverse effects from penbutolol due to decreased drug clearance.  Therapy with penbutolol should be administered cautiously in patients with liver disease.  Dosage adjustments may be necessary.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1962, 0, 'Penbutolol', 'Cerebrovascular Disorders', 'Beta-adrenergic blocking agents (beta-blockers), should be used with caution in patients with cerebrovascular insufficiency because of their potential effects relative to blood pressure and pulse.  If signs or symptoms suggesting reduced cerebral blood flow are observed, consideration should be given to discontinuing these agents.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1963, 0, 'Penbutolol', 'Glaucoma', 'Systemic beta-adrenergic receptor blocking agents (aka beta-blockers) may lower intraocular pressure.  Therefore, patients with glaucoma or intraocular hypertension may require adjustments in their ophthalmic regimen following a dosing change or discontinuation of beta-blocker therapy.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1964, 0, 'Penbutolol', 'Hyperlipidemias', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may alter serum lipid profiles.  Increases in serum VLDL and LDL cholesterol and triglycerides, as well as decreases in HDL cholesterol, have been reported with some beta-blockers.  Patients with preexisting hyperlipidemia may require closer monitoring during beta-blocker therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1965, 0, 'Penbutolol', 'Hyperthyroidism', 'When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm.  To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1966, 0, 'Penbutolol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1967, 0, 'Penbutolol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1968, 0, 'Penbutolol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1969, 0, 'Penbutolol', 'Tachycardia', 'Beta-adrenergic blockade in patients with Wolff-Parkinson-White syndrome and tachycardia has been associated with severe bradycardia requiring treatment with a pacemaker.  In one case, this result was reported after an initial dose of 5 mg propranolol.  The use of beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in these patients.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1970, 0, 'Penbutolol', 'Prinzmetal''s variant angina', 'Agents with non-selective beta-blocking activity may provoke chest pain in patients with Prinzmetal''s variant angina.  the use of non-selective beta blockers is not recommended in these patients.  Caution should be taken in the administration of these agents to patients suspected of having Prinzmetal''s variant angina.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1971, 0, 'Peginterferon alfa-2a', 'Kidney Diseases', 'Proteinuria (rare), not associated with a decrease in serum protein, is the most common renal toxicity observed with interferon- alfa therapy.  Increased BUN and serum creatinine levels, hematuria, acute renal failure and nephrotic syndrome have also been reported.  Therapy with interferon alfa should be administered cautiously to patients with severe renal dysfunction.  Renal function should be evaluated in all patients before initiation of interferon- alfa therapy.  In addition, patients with any degree of renal impairment should be carefully monitored for laboratory abnormalities and decreased creatinine clearance.  A reduced dose of medication is recommended in patients with low CrCl (less than 50 mL/min - 30 mL/min).', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1972, 0, 'Peginterferon alfa-2a', 'Autoimmune Diseases', 'Antiviral interferons may exacerbate autoimmune disorders such as myositis, thyroiditis, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, or autoimmune hepatitis.  Therapy should be avoided or administered with extreme caution in patients with autoimmune disorders.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1973, 0, 'Peginterferon alfa-2a', 'Heart Diseases', 'Hypertension, arrhythmias, angina, myocardial infarction, cardiomyopathy, and congestive heart failure have been reported during interferon therapy.  Therapy with interferons should be administered with caution in patients with compromised cardiac function.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1974, 0, 'Peginterferon alfa-2a', 'Hepatitis, Autoimmune', 'The use of peginterferons alfa are contraindicated in patients with autoimmune hepatitis.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1975, 0, 'Peginterferon alfa-2a', 'Depressive Disorder', 'Life-threatening or fatal neuropsychiatric reactions have been reported in patients receiving peginterferons alfa, including suicide, suicide ideation, homicidal ideation, depression, relapse of drug addiction, and drug overdose.  These reactions have occurred in patients with and without previous psychiatric illness.  These drugs should be used with extreme caution in patients with a history of depression.  Other events reported include aggressive behavior, psychosis, hallucinations, bipolar disorder and mania.  Patients should be monitored for any evidence of depression or other psychiatric symptoms, and they should be advised to report any signs or symptoms of depression or other changes in mood or behavior.  In severe cases, therapy should be stopped immediately and psychiatric intervention should be instituted.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1976, 0, 'Peginterferon alfa-2a', 'Liver Failure', 'The use of peginterferons alfa are contraindicated in patients with hepatic decompensation (Child-Pugh score greater than 6, class B or C) in cirrhotic patients before treatment, and in patients with hepatic decompensation (Child-Pugh score greater or equal to 6) that have chronic hepatitis C coinfected with HIV.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1977, 0, 'Peginterferon alfa-2a', 'Bone Marrow Failure Disorders', 'Peginterferons alfa suppress bone marrow function and may result in severe cytopenias.  Very rarely, it may be associated with aplastic anemia.  These drugs should be used with caution in patients with baseline neutrophil counts less than 1,500 cells/mm3, with platelet counts less than 90,000 cells/mm3 or baseline hemoglobin less than 10 g/dL.  It is advised that complete blood counts be obtained pretreatment and monitored routinely during therapy.  Neutropenia and thrombocytopenia occur with greater incidence in patients coinfected with HIV.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1978, 0, 'Peginterferon alfa-2a', 'Endocrine System Diseases', 'Peginterferons alfa can cause or aggravate hypothyroidism, hyperthyroidism, hyperglycemia, hypoglycemia and diabetes mellitus.  Treatment should be administered with caution on patients with these conditions.  Treatment should not be initiated if the condition cannot be effectively treated by medication.  Therapy should be discontinued if any of these conditions develops during treatment and it cannot be controlled with medication.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1979, 0, 'Peginterferon alfa-2a', 'Eye Diseases', 'Decrease or loss of vision, retinopathy including macular edema, retinal artery or vein thrombosis, retinal hemorrhages and cotton wool spots, optic neuritis, papilledema, and serious retinal detachment can be induced or aggravated by alpha interferons.  All patients should receive an eye examination at baseline and caution should be exercised in patients with preexisting ophthalmologic disorders.  Patients should have periodic ophthalmologic exams during treatment.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1980, 0, 'Peginterferon alfa-2a', 'Respiration Disorders', 'Dyspnea, pulmonary infiltrates, pneumonia, bronchiolitis, pulmonary hypertension, and other pulmonary disorders resulting in respiratory failure and/or death may be induced or aggravated by alpha interferon therapy.  Caution should be used when used in patients with preexisting pulmonary disorders.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1981, 0, 'Peginterferon beta-1a', 'Liver Diseases', 'Severe hepatic injury, including hepatitis, autoimmune hepatitis, cases of hepatic failure and asymptomatic transient increases in the concentrations of serum transaminases, have been reported in patients treated with beta interferons.  In some cases, these events have occurred in the presence of other drugs that have been associated with hepatic injury.  The potential risk of these agents used in combination with known hepatotoxic drugs or other products (e.g., alcohol) should be considered before starting therapy, or before starting hepatotoxic drugs.  Patients should be monitored for signs of hepatic injury, including the regular monitoring of liver function tests, and discontinuation of therapy should be considered if serum transaminase levels significantly increase or if hepatic injury occurs.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1982, 0, 'Peginterferon beta-1a', 'Autoimmune Diseases', 'Autoimmune disorders of multiple target organs including idiopathic thrombocytopenia, hyper- and hypothyroidism, and autoimmune hepatitis have been reported with interferon beta.  If patients develop a new autoimmune disorder, consider stopping therapy with this agent.  Care and close monitoring is recommended when prescribing this agent to patients at risk of developing an autoimmune disorder.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1983, 0, 'Peginterferon beta-1a', 'Heart Failure', 'Congestive heart failure, cardiomyopathy, and cardiomyopathy with congestive heart failure occur in patients receiving interferon beta.  It is recommended to monitor patients with significant cardiac disease for worsening of their cardiac condition during initiation and continuation of treatment.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1984, 0, 'Peginterferon beta-1a', 'Pancytopenia', 'Interferon beta can cause decreased peripheral blood counts in all cell lines, including rare instances of pancytopenia and severe thrombocytopenia.  It is recommended to monitor patients for infections, bleeding, and symptoms of anemia.  Monitor complete blood cell counts, differential white blood cell counts, and platelet counts during treatment.  Close monitoring is recommended when prescribing this agent to patients at risk, in particular to patients with myelosuppression.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1985, 0, 'Peginterferon beta-1a', 'Depressive Disorder', 'Depression, suicidal ideation, and suicide have been reported in patients receiving peginterferon beta.  Patients should be monitored for any evidence of depression or other psychiatric symptoms.  Patients should be advised to report any signs or symptoms of depression, or other changes in mood or behavior.  In severe cases, therapy should be stopped immediately and psychiatric intervention should be instituted.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1986, 0, 'Peginterferon beta-1a', 'Injection Site Reaction', 'Injection site reactions, including injection site necrosis, can occur with the use of subcutaneous interferon beta.  Caution should be exercised when prescribing this agent and the decisions to discontinue therapy following necrosis at a single injection site should be based on the extent of the necrosis.  For patients who continue therapy after injection site necrosis has occurred, it is recommended to avoid administration of this agent near the affected area until it is fully healed and if multiple lesions occur, discontinue therapy until healing occurs.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1987, 0, 'Peginterferon beta-1a', 'Kidney Diseases', 'Pharmacokinetic studies have shown that renal impairment can increase the Cmax of Peginterferon beta-1a.  Caution should be taken when prescribing this agent to these patients.  It is recommended to monitor renal function, and to monitor for adverse reactions due to increased drug exposure in patients with severe renal impairment.  Clinical monitoring of renal function is recommended.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1988, 0, 'Peginterferon beta-1a', 'Seizures', 'The use of peginterferon beta-1a may cause seizures.  Exercise caution when prescribing this agent to patients with a history of seizure disorders.  Close monitoring is recommended.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1989, 0, 'Peginterferon beta-1a', 'Thrombotic Microangiopathies', 'Cases of thrombotic microangiopathy (TMA), including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, some fatal, have been reported with interferon beta products.  Discontinue therapy if clinical symptoms and laboratory findings are consistent with TMA, and manage as clinically indicated.  Care should be taken when prescribing this agent to patients at risk of endothelial injury.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1990, 0, 'Pentazocine', 'Gastrointestinal Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the gastrointestinal tract and decrease peristalsis, which can lead to elevated intraluminal pressure, spasm, and constipation following prolonged use.  In patients with severe or acute inflammatory bowel disease, the decrease in colonic motility may induce toxic megacolon.  Therapy with opioids should be administered cautiously in patients with gastrointestinal obstruction, constipation, inflammatory bowel disease, or recent gastrointestinal tract surgery.  Gastrointestinal effects appear to be the most pronounced with morphine.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1991, 0, 'Pentazocine', 'Dysentery', 'Narcotic (opioid) analgesic agents may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella, Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  These agents decrease gastrointestinal motility, which may delay the excretion of infective gastroenteric organisms and/or their toxins.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  Therapy with opioids should be avoided or administered cautiously in patients with infectious diarrhea, particularly that due to pseudomembranous enterocolitis or enterotoxin-producing bacteria or if accompanied by high fever, pus, or blood in the stool.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1992, 0, 'Pentazocine', 'Liver Diseases', 'Narcotic (opioid) analgesic agents are extensively metabolized by the liver, and several of them (e.g., codeine, hydrocodone, meperidine, methadone, morphine, propoxyphene) have active metabolites that are further converted to inactive substances.  The serum concentrations of these agents and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with liver disease.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1993, 0, 'Pentazocine', 'Premature Birth', 'The use of narcotic (opioid) analgesic agents is contraindicated in premature infants.  These agents may cross the immature blood-brain barrier to a greater extent than in adults, resulting in disproportionate respiratory depression.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1994, 0, 'Pentazocine', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1995, 0, 'Pentazocine', 'Myocardial Infarction', 'Opiate partial agonists may increase systemic and pulmonary arterial pressure and systemic vascular resistance, particularly when given by intravenous administration.  Data are available for pentazocine and butorphanol.  Therapy with opiate partial agonists should be administered cautiously and only if the benefit justifies the risk in patients with acute myocardial infarction (especially if accompanied by hypertension or left ventricular failure) or coronary insufficiency.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1996, 0, 'Pentazocine', 'Substance-Related Disorders', 'Opiate partial agonists have the potential to cause dependence and abuse, particularly in patients with a history of drug abuse.  Tolerance as well as physical and psychological dependence can develop after prolonged use, and abrupt cessation or a significant reduction in dosage may precipitate withdrawal symptoms.  Because of their opiate antagonistic effect, withdrawal symptoms may also occur if opiate partial agonists are administered to patients with an opiate dependence or in whom substantial amounts of narcotics have recently been administered.  Therapy with opiate partial agonists is not recommended in patients who are physically dependent on narcotics.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with opiate partial agonists.  It may be prudent to refrain from dispensing large quantities of medication to these patients.  After prolonged use or if dependency is suspected, withdrawal of opiate therapy should be undertaken gradually using a dosage-tapering schedule.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1997, 0, 'Pentazocine', 'Intracranial Hypertension', 'The hypoventilation associated with administration of opiate partial agonists can induce cerebral hypoxia and vasodilatation with resultant increase in intracranial pressure.  Unless mechanical ventilation is provided, extreme caution is advised when opiate partial agonists are given to patients head injury, intracranial lesions, or a preexisting elevated CSF pressure.  Also, clinicians treating such patients should be aware that opiate partial agonists may interfere with the evaluation of CNS function, especially with respect to consciousness levels, respiratory status, and pupillary changes.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1998, 0, 'Pentazocine', 'Respiratory Insufficiency', 'Opiate partial agonists may produce respiratory depression by decreasing respiratory drive and increasing airway resistance.  A "ceiling effect" has been noted for these agents, and increasing doses do not produce proportional or further respiratory depression.  However, the duration of effect is prolonged.  At therapeutic analgesic dosages, the respiratory effects are usually not clinically important except in patients with preexisting pulmonary impairment.  Therapy with opiate partial agonists should be avoided or administered with extreme caution and initiated at reduced dosages in patients with severe CNS or respiratory depression; acute alcohol intoxication; sleep apnea; hypoxia, anoxia, or hypercapnia; upper airway obstruction; chronic pulmonary insufficiency; a limited ventilatory reserve; or other respiratory disorders.  In the presence of excessive respiratory secretions, the use of opiate partial agonists may also be problematic because they decrease ciliary activity and reduce the cough reflex.  Caution is also advised in patients who may be at increased risk for respiratory depression, such as comatose patients or those with head injury, intracranial lesions, or intracranial hypertension.  Clinical monitoring of pulmonary function is recommended, and equipment for resuscitation should be immediately available if parenteral routes are used.  Naloxone may be administered to reverse clinically significant respiratory depression.  However, in the case of buprenorphine, naloxone may not be effective due to buprenorphine''s slow rate of dissociation from mu receptors.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1999, 0, 'Pentazocine', 'Adrenal Insufficiency', 'Patients with Addison''s disease may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  Conversely, these agents may cause or potentiate adrenal insufficiency.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with adrenocortical insufficiency.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (2000, 0, 'Pentazocine', 'Gallbladder Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the biliary tract, which can lead to spasm and elevated biliary tract pressure, especially in the sphincter of Oddi.  Biliary effects appear to be the most pronounced with morphine, although they do not always occur with therapeutic doses.  Therapy with opioids should be administered cautiously in patients with biliary or gallbladder disease.', '2', 'DDInter', 0);
